# IOWA STATE UNIVERSITY Digital Repository

**Retrospective Theses and Dissertations** 

Iowa State University Capstones, Theses and Dissertations

1950

# Factors concerned in tyrosine metabolism

Richard S. Schweet Iowa State College

Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Biochemistry Commons

#### **Recommended** Citation

Schweet, Richard S., "Factors concerned in tyrosine metabolism " (1950). *Retrospective Theses and Dissertations*. 13088. https://lib.dr.iastate.edu/rtd/13088

This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu.



# NOTE TO USERS

This reproduction is the best copy available.



## FACTORS CONCERNED IN TYROSINE METABOLISM

by

Richard S. Schweet

# A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of

DOCTOR OF PHILOSOPHY

Major Subject: Physiological and Nutritional Chemistry

Iowa State College

1950

## Approved:

Signature was redacted for privacy.

In Charge of Major Work

Signature was redacted for privacy.

Head of Major Department

Signature was redacted for privacy. **Dean of Graduate College** 

### UMI Number: DP12306

## INFORMATION TO USERS

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.



## UMI Microform DP12306

Copyright 2005 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code.

> ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346

# Q P 5 5 1 Sch 99f

# 1126-3

#### ACKNOWLEDGMENT

The writer wishes to express his sincere appreciation to Dr. Robert R. Sealock for his suggestion of this problem and his guidance in the development of it.

T9371

## TABLE OF CONTENTS

|      |     |       |               |      |            |            |            |     |     |      |      |      |            |            |         |            |            |   |     |   |            |     | Page |
|------|-----|-------|---------------|------|------------|------------|------------|-----|-----|------|------|------|------------|------------|---------|------------|------------|---|-----|---|------------|-----|------|
|      | ACI | KN OV | VLED          | GME  | n <b>T</b> | •          | • •        | ٠   | ٠   | •_j  | •    | •    | •          | ٠          | ٠       | *.         | •          | ٠ | •   | • | ; <b>•</b> | ٠   | 11   |
| I.   | INT | rroi  | DUCT          | ION  | .*         | <b>ب</b> د | • •        | •   | •   | •    | • .  | ٠    | •          |            | •       | •          | •          |   | ٠   | ٠ | ٠          | •   | 1    |
| II.  | HIS | STOF  | RICA          | L.   | •          | •          | • •        | .•. | ٠   | ٠    | •    | •    | ٠          | ŧ          | •       | •          | •          | ٠ | •   | • | •          | •   | 4    |
|      | A.  | Tyı   | ro <b>s</b> 1 | ne   | Met        | tab        | oli        | sm  | in  | G    | en   | er   | <b>a</b> 1 |            | •       | •          | •          | • | •   | ٠ | •          | ٠   | 4    |
|      | в.  | Vit   | ami           | n C  | a1         | nd         | Tyr        | 08  | ine | M    | let  | ab   | ol         | is         | m       | .*         | ٠          | • | •   | • | •          | ٠   | 14   |
|      | c.  | Liv   | er            | Ext  | rac        | ots        | øn         | d ! | ſyr | os   | in   | 0    | Me         | ta         | bo      | 11         | sn         | 1 | . # | ٠ | ٠          | ٠   | 18   |
|      |     | 1.    |               |      |            |            | yro<br>hip |     | ne- | 11   | .ve  | r    | ex<br>•    | tr         | ac<br>• | t          | ٠          | • | •   | • | •          | ÷   | 18   |
|      |     | 2.    | Mul           | .tip | le         | na         | tur        | e   | of  | 11   | .v.e | r    | fa         | ct         | or      | 8          | •          | • | ٠   | • | ٠          | •   | 22   |
|      | D.  | Fol   | Lic           | Aci  | d s        | anđ        | Ту         | ro  | sin | 8    | Me   | ta   | bo         | 11         | sm      | L          | •          | ٠ | •   | • | •          | ٠   | 32   |
|      | E.  | Oti   | er            | Die  | ta         | ry         | Fac        | to  | rs  |      | •    | •    | •          | •          | •       | •          |            | ٠ | ٠   | • | ٠          | •   | 39   |
|      |     | 1.    | Ami           | no   | ac         | ids        | an         | đ   | oth | er   | v v  | it   | am         | in         | 8       |            | •          | • | •   | • | •          | •   | 39   |
|      |     | 2.    | Pur           | ifi  | .ed        | di         | ets        | ſ   | or  | gu   | in   | .88  | p          | ig         | ;8      | ٠          | <b>•</b> . | ٠ | •   | ٠ | •          | ٠   | 40   |
|      | F.  | Isc   | otop          | e S  | stud       | iie        | <b>s</b> 0 | f   | Tyr | os   | in   | 0    | Me         | ta         | bc      | 11         | sn         | n |     | • | •          | ٠   | 42   |
| III. | EX  | PERI  | I MEN         | TAI  | đe         | • -        | • •        | •   | ٠   | ٠    |      | ٠    | •          |            | •       | •          | *          | • | . • | ٠ | ٠          | ∳1  | ້ 50 |
|      | A.  | Efi   | rect          | :s c | of (       | Con        | cen        | tr  | ate | d    | Li   | .ve  | r          | Ex         | tr      | ac         | eta        | 3 | •   | • | ٠          | •   | 50   |
|      |     | 1.    | Met           | hoć  | ls         | ٠          | * *        | ٠   | ٠   | ٠    | •    | •    | ٠          | •          | •       | *          | •          | • | ٠   | • | ٠          | ٠   | 50   |
|      |     | 2.    | Ans           | lys  | is         | of         | 88         | sa  | УF  | rc   | oce  | du   | re         | <b>i</b> . | •       | •          | •          | ٠ | •   | ٠ | •          | ٠   | 52   |
|      |     | 3.    | Cha           | rac  | te:        | ris        | tic        | 8   | of  | ac   | ti   | ve   | ) `a       | ge         | nt      | <b>.</b> . | ٠          | ٠ | •   | ٠ | ٠          | . • | 67   |
|      |     | 4.    |               |      |            |            | ct<br>tor  |     | •   | on f | jun  | te t | ic<br>•    | n<br>•     | wj      | tł         | 1<br>•     | • | •   | ٠ | •          | •   | 72   |
| ,    |     | 5.    | Use           | o of | t pi       | uri        | fie        | đ   | die | ət   | •    | •    | •          | ٠          | ٠       | •          | •          | • | •   | ٠ | ٠          | ٠   | 76   |

- 111 -

|        |    |     |     |     |     |   |     |    |    |    |    |     |     |     |     |      |   |   |    |    |     |   |   |   | Page |
|--------|----|-----|-----|-----|-----|---|-----|----|----|----|----|-----|-----|-----|-----|------|---|---|----|----|-----|---|---|---|------|
|        |    | 6.  | Ef  | fec | ets | C | on  | Ъ. | lo | bd | 00 | ons | sti | Lti | ıer | 1 te | 3 | ٠ | •  | .• | ٠   | ٠ |   | ٠ | 83   |
| •<br>• | в. | Exj | per | ime | nt  | 8 | Us  | 11 | ng | N  | 15 | -L- | -T3 | T   | 281 | ine  | Э | • | ٠  | *  | •   | • | • | ٠ | 98   |
|        |    | 1.  | Me  | the | ods | ł | •   |    | •  | •  |    | ٠   | ٠   | •   | ٠   | ٠    | ٠ | ٠ | ٠  | ٠  | •   | ٠ | ٠ | ٠ | 98   |
|        |    | 2.  | Re  | sul | Lts | ł | . • | ٠  |    | •  |    | •   | ۲   | •   | ٠   | ٠    | ٠ | • | •  |    | ٠   | ٠ | ٠ | ٠ | 112  |
| IV.    | DI | SCU | 581 | ON  | •   | ٠ | ٠   | •  | •  |    | ٠  | •   | ٠   | ٠   | •   | ٠    | ٠ | ٠ | .• | ٠  | . • |   | ٠ | ٠ | 123  |
| v.     | SU | MMA | RY  | •   | ٠   | ٠ | ٠   | •. | ¥  | •  | ٠  | •   | ٠   | •   | ٠   | ٠    | • | ٠ | ٠  | •  | ٠   | ٠ | ٠ | • | 130  |
| VI.    | BI | BLI | OGF | API | IY  | • | ٠   | •  | •  | •  | ٠  | •   | ٠   | ٠   | ٠   | ٠    | • | ٠ | •  | •  | ٠   | • | • | • | 132  |
|        |    |     |     |     |     |   |     |    |    |    |    |     |     |     |     |      |   |   |    |    |     |   |   |   |      |
|        |    |     |     |     |     |   |     |    |    |    |    |     |     |     |     |      |   |   |    |    |     |   |   |   |      |

. . . .

•

#### I. INTRODUCTION

Studies of the intermediary metabolism of amino acids have assumed increasing importance in recent years. These studies have been stimulated not only by the importance of amino acids in nutrition but also by recent findings implicating various vitamins as components of enzyme systems involved in the metabolism of amino acids. Besides providing new concepts of the functioning of vitamins in the body, our understanding of nutritional deficiency diseases has been clarified by the investigations of vitamin-amino acid interrelationships.

The metabolism of the aromatic amino acids, phenylalanine and tyrosine, has been studied extensively. Some of the findings which have been responsible for the widespread interest in these two compounds are: phenylalanine is an essential amino acid and is readily converted to tyrosine in the body, thyroxine and adrenaline may be derived from tyrosine, melanin pigments are formed from tyrosine, and finally, certain diseases are characterized or accompanied by an abnormal utilization of the aromatic amino acids so that partial breakdown products appear in the urine. These disorders include some of the "inborn errors" of metabolism, hydroxyphenyluria in premature infants, pernicious anemia

- 1 -

in relapse, certain cyanotic conditions, and rheumatic fever.

Many of the investigations, however, have been of a clinical nature or have been concerned with the intermediates produced in tyrosine catabolism. With the finding that the vitamin C-deficient guinea pig fails to metabolize tyrosine completely, a new approach to the problem under controlled experimental conditions was made possible. This approach has now shown that pteroylglutamic acid and a factor found in purified liver extracts, in addition to vitamin C, are components concerned in tyrosine metabolism.

The present investigation is an attempt to investigate further the mechanism by which these factors act on tyrosine metabolism in the vitamin C-deficient guinea pig. Liver extracts used for the treatment of pernicious anemia were studied extensively in order to analyze the testing procedure, study the relationship between their antipernicious anemia unitage and their activity in the tyrosine metabolic system, investigate the nature of the substance in the extracts responsible for their action and finally, examine their action on blood constituents under varied experimental conditions.

The advent of isotopes as tracers provided a new, powerful tool for metabolic research. With the tyrosine molecule marked in various positions, the utilization of the amino acid under the influence of the three factors under

- 2 -

investigation could be followed. Initial studies of the first step, with  $N^{15}$  in the amino group of the molecule, are reported here. Further work along these lines may eventually result in the assignment of specific chemical functions in the tyrosine metabolic scheme to these factors.

#### II. HISTORICAL

A. Tyrosine Metabolism in General

The initial impetus to the study of tyrosine metabolism came from the work of Bödeker (1). In 1859, this author isolated a reducing compound from the urine of diabetic patients. He was unable to identify the substance, but called it "alkapton." Later, Wolkow and Baumann (2) established the structure of the compound as hydroquinone acetic acid on the basis of its empirical formula and functional groups. They called the compound homogentisic acid, the next higher homologue of gentisic acid.

They further discovered that tyrosine was the precursor of the homogentisic acid excreted by feeding extra amounts of the amino acid to persons with alcaptonuria. Falta and Langstein (3) later showed that phenylalanine also was converted to homogentisic acid by the alcaptonuric.

In 1904, Neubauer and Falta (4) investigated the metabolism of a number of aromatic compounds by the alcaptonuric. The only compounds, in addition to the two amino acids, which yielded homogentisic acid were phenylpyruvic and phenyllactic acids. Later, <u>p</u>-hydroxyphenylpyruvic, but not <u>p</u>-hydroxyphenyllactic acid, was also found to yield homogentisic acid in the alcaptonuric (5).

- 4 -


In 1906, Embden, Salomon and Schmidt (6) applied perfusion techniques to the study of alcaptonuria. They found that when tyrosine, phenylalanine and homogentisic acid were perfused through surviving liver, acetone bodies appeared in the effluent. The ketogenic nature of the aromatic amino acids was confirmed by Blum (7) when he showed that feeding these compounds to diabetics produced an increased excretion of ketone bodies. Edson (8) has demonstrated the ketogenic nature of tyrosine and phenylalanine using the Warburg technique and rat liver slices.

The mechanisms involved in the conversion of tyrosine to ketone bodies were also discussed by Blum (7). Since  $\underline{p}$ -hydroxyphenylacetic acid did not give homogentisic acid in the alcaptonuric patient, he felt that oxidation of the tyrosine aromatic nucleus occurred prior to sidechain degradation. In addition, Blum thought that homogentisic acid was a normal intermediate in tyrosine oxidation although he was unable to isolate the compound from normal individuals.

Neubauer (5) combined all of these results into a scheme for the normal oxidation of tyrosine and phenylalanine. This scheme postulated a "quinol-type" intermediate. Quinols had previously been prepared by several authors, particularly Bamberger (9). Neubauer believed that the first step in amino acid catabolism was oxidative de-amination yielding the corresponding keto acid. For the aromatic amino acids,

- 5 -

he proposed the following scheme:




Evidence for the conversion of phenylalanine to tyrosine had previously been given by the perfusion experiments of Embden and Baldes (10). However, these authors noted that

6 -

phenylpyruvic acid when perfused through surviving liver, in contrast to the p-hydroxy compound, did not yield acetone bodies. They favored, therefore, Reaction A over Reaction B as part of the normal pathway of metabolism. Moss and Schoenheimer (11) have recently confirmed the conversion of phenylalanine to tyrosine by the use of deuterium-labelled phenylalanine.

In 1910, Dakin (12) was able to point out some flaws in Neubauer's hypotheses. He showed that compounds such as <u>p</u>-methoxyphenylalanine and <u>p</u>-methylphenylalanine (13), which supposedly could not yield the quinol postulated by Neubauer, were still metabolized by normal individuals. These compounds yielded acetone bodies when perfused through liver and were metabolized by alcaptonurics without production of homogentisic acid. Dakin (14) concluded that homogentisic acid need not be a normal intermediate in tyrosine oxidation. Since Jaffe (15) had shown benzene was oxidized to muconic acid by dogs, Dakin (13) proposed a scheme which did not involve the introduction of hydroxyl groups into the tyrosine nucleus:




Dakin's views have received support from the work of Fromherz and Hermanns (16, 17). These authors found that <u>p</u>-methyltyrosine and <u>m</u>-methyltyrosine were metabolized by both normal and alcaptonuric individuals without the production of homogentisic acid derivatives, thus confirming Dakin's work.

The most recent investigations of alcaptonuria have been made by Neuberger and colleagues. In 1947, Neuberger, Rimington and Wilson (18) reported that 80-100% of ingested tyrosine or phenylalanine appeared in the urine as homogentisic acid. The low blood values of homogentisic acid led them to suggest that this compound was either formed in the kidney or excreted at an extremely rapid rate. Later, Neuberger (19, 20) fed L-2,5-dihydroxyphenylalanine and noted its efficient conversion to homogentisic acid. He considered this compound, therefore, a normal intermediate in the

- 8 -

exidation of tyrosine. The mechanism involved in the normal metabolism of tyrosine as suggested by Neuberger (21) utilizes some of the more modern concepts of organic chemistry to explain the postulated scheme. The phenoxide ion (1) is attacked by an electrophilic reagent. Preferential attack in the para position might be facilitated by the side chain constitution or the enzyme. The removal of two electrons produces a carbonium ion (11). Attack by hydroxyl ion and rearrangement of the p-quinol (111) follows, yielding 2,5-dihydroxyphenylalanine as a final product. Similar rearrangements have been shown by Arnold (22).



- 9 -

In the light of these recent studies, it would seem that homogentisic acid was an intermediate in the main pathway of tyrosine catabolism, as Neubauer had postulated in 1909. However, the evidence has been indirect and based to a large extent on the study of alcaptonuria. Alternate pathways of oxidation certainly exist and the possibility that they play an important role in tyrosine metabolism has not been excluded. In addition, it should be noted that the mechanisms postulated are even more obscure. None of the important intermediates have been isolated in normal individuals. Finally, if homogentisic acid is a normal intermediate, little is known of the route by which it is converted to acetoacetic acid.

In 1932, Medes (23) reported another "inborn error" of metabolism. This patient excreted <u>p</u>-hydroxyphenylpyruvic acid in the urine. The feeding of phenylalanine or tyrosine increased the excretion of this compound. Homogentisic acid was metabolized completely. This tyrosinosis, as Medes called the defect, resulted also in the excretion of 3,4-dihydroxyphenylalanine when large amounts of tyrosine were fed. Thus, further proof for the conversion of phenylalanine to tyrosine was obtained and also evidence of the oxidation of tyrosine in the <u>meta</u> position. The latter finding implicated tyrosine as a possible melanin and adrenaline precursor. Gurin and Delluva (24) have shown the oxidation of tritium-labelled phenylalanine to adrenaline, presumably through the prior formation of a 3,4-dihydroxy compound. The conversion of 3,4-dihydroxyphenylalanine to melanin has been well established by the work of Raper (25) and more recently by Mason (26).

In addition to the utilization of phenylalanine by way of conversion to tyrosine, other metabolic pathways are known. Womack and Rose (27) have shown that phenylalanine is an essential amine acid while tyrosine is not. That this difference can be reflected in the metabolic pathway has been demonstrated by Butts, Dunn and Hallman (28). In their first experiments racemic tyrosine and phenylalanine were fed to rats and the liver glycogen content and urinary ketone bodies (after sodium butyrate feeding) determined. Phenylalanine feeding caused increased liver glycogen, slightly decreased acetonuria and increased urinary nitrogen. Alanine produced effects similar to those of phenylalanine, but in greater amount. Tyrosine caused no change in any of these values. Later (29) it was found that fasted rats, when fed L-tyrosine, showed an increase in liver glycogen, in contrast to the negative findings when DL-tyrosine was fed. The glycogenic effect of tyrosine has been recently confirmed. This work will be discussed in Section F.

Defects in tyrosine metabolism have been reported in two other diseases. Fishberg (30) noted that cyanotic patients

- 11 -

excreted a tyrosine metabolite in the urine. This was identified as the quinone of homogentisic acid. The author hypothesized that the oxidizing action of this compound produced the methemoglobin characteristic of the disease. Some interruption of tyrosine catabolism, possibly related to the vitamin C intake, was believed responsible for the accumulation of the metabolite. Kemmerer (31) has noted the appearance of tyrosine derivatives in the urine of patients with rheumatic arthritis. These patients had the same food intake as controls who did not excrete these compounds.

The early in vitro studies of tyrosine metabolism by Neubauer and Embden, using perfusion methods were followed by the adaptation of Warburg manometric techniques to the In 1934, Bernheim and Bernheim (32) studied the problem. oxidation of tyrosine and phenylalanine with "broken cell suspensions." Tyrosine was oxidized best by liver tissues with the uptake of four atoms of oxygen per mole of tyrosine under optimum conditions. No ammonia was produced. In contrast, phenylalanine was oxidized by both liver and kidney, ammonia was produced, and the oxygen uptake was one atom per Cyanide inhibited the tyrosine system but not that of mole. phenylalanine. A year later, Bernheim (33) showed that not only were the natural isomers of phenylalanine and tyrosine oxidized by different enzyme systems, but that the oxidation of D-tyrosine differed from that of the L-isomer, since kidney, as well as liver tissue, attacked the unnatural

- 12 -

isomer. The oxidation of D-tyrosine by liver tissue, in contrast to the natural isomer, was accompanied by ammonia production and was not inhibited by potassium cyanide.

Felix and coworkers (34) were able to separate tyrosine oxidation by hog liver into four steps by means of pH differences in the brei. The end products of the reaction were acetone and carbon dioxide. Homogentisic acid and <u>p</u>-hydroxyphenylpyruvic acid were also oxidized. Felix and Schaefer (35) have reported the extraction of an enzyme system from rat liver which oxidized <u>p</u>-hydroxyphenylpyruvic acid with the uptake of 3 atoms of oxygen per mole. These findings do not necessarily indicate that this keto acid is a normal intermediate in tyrosine oxidation, since neither ammonia nor <u>p</u>-hydroxyphenylpyruvic acid have been reported as products of the <u>in vitro</u> oxidation of tyrosine. Furthermore, the work of Neuberger (19), which will be discussed further in Section E, has indicated that 2,5-dihydroxyphenylalanine is an important intermediate in tyrosine metabolism.

In a later paper, Felix and associates (36) detected alanine as one of the products of tyrosine breakdown. Their results agreed with the Neubauer scheme, except for the alanine cleavage. They believed that the tyrosine nucleus only was oxidized to the acetone bodies formed during the incubation. Recent work, which will be discussed in Section F, has shown that side chain cleavage of tyrosine

- 13 -

during its exidation to acetoacetic acid cannot take place to any large extent. Their isolation of alanine is thus difficult to explain.

As some of the questions concerned with tyrosine metabolism were clarified it became apparent that studies of the rare alcaptonuric individual and normal tissues <u>in vitro</u> would have to be supplemented by controlled laboratory experiments. Experimental alcaptonuria and other defects in tyrosine utilization were soon produced by appropriate changes in dietary factors. A discussion of each of these factors and its relation to the tyrosine problem will be given in the following sections.

#### B. Vitamin C and Tyrosine Metabolism

As early as 1930, prior to its actual identification as vitamin C, Szent-Györgyi (37) noted that "hexuronic acid" inhibited the formation of melanin pigments. The pigmentation (38) associated with Addison's disease was decreased by vitamin C supplementation.

In 1939, Sealock and associates (39) investigated further the vitamin C-melanin relationship. They fed the melanin precursors, tyrosine and 3,4-dihydroxyphenylalanine, to scorbutic and normal guinea pigs. It was noted that the vitamin C requirement was increased when these amino acids were fed. In addition, the urines of the vitamin-deficient animals receiving extra tyrosine darkened on standing. Examination revealed the presence of homogentisic acid in these urines. This compound was isolated and its identity definitely established.

The production of experimental alcaptonuria had also been reported the previous year, first by Papageorge and Lewis (40) and then by Butts, Dunn and Hallman (28). Homogentisic acid excretion in these cases was the result of the feeding of large amounts of phenylalanine to white rats. However, the guinea pig picture was due to a definite vitamin deficiency, the levels of tyrosine fed were smaller, and the conversion of the amino acid to excreted metabolites was nearly complete when the vitamin deficiency was acute.

Sealock and Silberstein (41) then showed that administration of vitamin C caused the disappearance of the urinary metabolites. When 0.5 gm. of tyrosine was fed, administration of 5.0 mg. of the vitamin resulted in removal of the metabolites from the urine. Similar tests on normal human subjects also resulted in homogentisic acid excretion. The difference between this type of alcaptonuria and the hereditary type was emphasized when it was shown by Sealock, Galdston and Steele (42) that vitamin C did not affect the homogentisic acid excretion of the hereditary alcaptonuric. Further work by Sealock and Silberstein (43) revealed the presence of p-hydroxyphenylpyruvic and p-hydroxyphenyllactic

- 15 -

acids among the excretory products, in addition to homogentisic acid. The feeding of L-phenylalanine to the vitamin C-deficient guinea pig also resulted in the production of these same excretory products. Vitamin C produced its curative effect here also. The specificity of the vitamin in this connection was demonstrated by the fact that 10 mg. of D-isoascorbic acid was ineffective in removing the metabolites. However, 200 mg., an amount equal in antiscorbutic activity to 10 mg. of L-ascorbic acid, was able to prevent the metabolite excretion. Phenylpyruvic acid metabolism (44), but not that of the <u>p</u>-hydroxy derivative, was also influenced by vitamin C administration.

The clinical application of these findings appeared shortly when Levine, Marples and Gordon (45) demonstrated that the hydroxyphenyluria noted in premature infants on a cow's milk formula (high protein level) was prevented by vitamin C. The defect could also be demonstrated (46, 47) in full-term infants by the feeding of a single dose of 1.0 gm. of tyrosine in the absence of vitamin C. Both the artificially induced and natural hydroxyphenyluria were corrected by the proper vitamin C intake and the authors emphasize the importance of the vitamin in the diet of infants.

In 1942, Sealock (48) found that the administration of dicarboxylic acids resulted in removal of the uninary

- 16 -

metabolites of guinea pigs receiving extra tyrosine on a vitamin C-free diet. The effect, however, was temporary, and repeated doses gradually lost their effect. The action was shown to be the result of the acidity changes which mobilized tissue vitamin C and could be duplicated by the use of ammonium chloride. The acid-base balance, therefore, must be considered when experiments of this type are undertaken.

In vitro studies by Lan and Sealock (49) with liver and kidney slices of normal guinea pigs demonstrated an increased oxygen uptake in the presence of tyrosine substrate. Slices of these tissues from scorbutic animals did not exhibit this increased oxygen consumption, but the addition of crystalline ascorbic acid to the Warburg flasks restored their ability to oxidize tyrosine. These same authors (50) extended their studies to 3,4-dihydroxyphenylalanine and demonstrated a similar dependence on an adequate vitamin C supply. In the case of this amino acid the most active oxidation took place with kidney slices, while liver slices were most important with the former.

Sealock and Goodland (51) have prepared cell-free homogenates of guines pig liver which oxidized tyrosine with the uptake of 4 atoms of oxygen per mole of tyrosine oxidized. The system was shown to contain thermostable, dialyzable components. Similarly, Sealock and Clegg (52) have shown that cell-free preparations from kidney tissue will oxidize

- 17 -

#### 3,4-dihydroxyphenylalanine.

We may conclude that the dependence of tyrosine utilization upon adequate vitamin C intake has been established. The demonstration of the <u>in vitro</u> vitamin function in tyrosine oxidation, and the characterization of the crude enzyme systems responsible, represent further progress in clarifying the problem. These studies point to the action of vitamin C at an early stage in tyrosine breakdown. However, as yet no specific location of the vitamin action in the postulated oxidative scheme involving homogentisic acid has been reported. Furthermore, the function of the vitamin in tyrosine metabolism <u>in vivo</u> may be more complex than <u>in vitro</u> studies seem to indicate. These questions, and the more difficult one of the interrelationship of vitamin C with other factors regulating tyrosine metabolism, constitute the subject matter of continuing research.

C. Liver Extracts and Tyrosine Metabolism

1. Origin of tyrosine-liver extract relationship

In 1941, in connection with their work on the hydroxyphenyluria noted in premature infants, Levine and coworkers (47) had tried liver extract as a curative agent. This extract was a crude liver extract, free from vitamin C. Administration of this preparation reduced the metabolite

- 18 -

excretion of one premature infant and one full-term infant that had been receiving extra tyrosine, but had no effect on three other premature infants.

In 1943, Swendseid and associates (53) reported an increased urinary excretion of keto acids by patients with untreated pernicious anemia. After treatment by intramuscular injection of liver extract, the keto acid levels returned to normal. Correlation of keto acid with hydroxyphenyl values, as shown in Table I, suggested a disturbance in tyrosine metabolism. Ten normal patients on the same hospital diet showed average values of 82 and 195 mg. per 24 hours for urinary keto acid and hydroxyphenyl compounds, respectively.

#### Table I

## Daily Urinary Excretion Values for Keto Acids and Hydroxyphenyl Compounds in Pernicious Anemia

|         |      | xpressed<br>id in mg.<br>hr. |      | Hydroxyphenyl compounds<br>expressed as tyrosine in<br>mg. per 24 hr. |      |           |      |  |  |  |  |
|---------|------|------------------------------|------|---|------|-----------|------|--|--|--|--|
| Relaps  | e    | Remiss                       | sion | Relaps  | 36   | Remission |      |  |  |  |  |
| Range   | Avg. | Range                        | Avg. | Range   | Avg. | Range     | Avg. |  |  |  |  |
| 228-177 | 202  | 107-94                       | 99   | 714-444   | 584  | 292-242   | 278  |  |  |  |  |
| 158-107 | 135  | 63-56                        | 60   | 799-427   | 513  | 290-270   | 280  |  |  |  |  |
| 1534103 | 138  | 97-68                        | 76   | 428-308   | 400  | 260-201   | 219  |  |  |  |  |
| 135-124 | 127  | 93-74                        | 82   | 682-362   | 442  | 287-240   | 256  |  |  |  |  |

Further work in 1947 by this group (54) confirmed these results. Fractionation of the urine revealed that the portion containing the hydroxyphenyl acids showed the greatest decrease when liver extract was administered. This decrease was the first effect of therapy and preceded any blood changes. Vitamin C administration had no effect on patients with normal plasme levels of the vitamin. The authors suggested a possible function of tyrosine in blood formation, and thus linked the derangement of tyrosine metabolism observed directly to the anemia.

On the basis of these facts, Sealock and Lepow (55) investigated the effect of antipernicious anemia preparations on the metabolite excretion of scorbutic guinea pigs receiving extra tyrosine. These preparations contained an insignificant amount of vitamin C and pteroylglutamic acid. The prompt decrease in keto acid excretion (paralleled by total phenolic values) observed is shown in Table II. It is evident that with a given preparation the effect is roughly correlated with the number of units injected. Other liver extracts yielded similar results, although correlation between different extracts was poor. These extracts did not increase the <u>in vitro</u> oxidation of tyrosine by liver tissue, as has been reported for ascorbic acid and pteroylglutamic acid (to be discussed in Section D).

- 20 -

# Table II

# Keto Acid Excretion Before and After Liver Extract Injection

| Liver extract<br>injected | Keto acid excretion |              |                        |  |  |  |  |  |  |  |  |
|---------------------------|---------------------|--------------|------------------------|--|--|--|--|--|--|--|--|
| Trifie 0 000              | 24 hr. before       | 24 hr. after | % decrease<br>per unit |  |  |  |  |  |  |  |  |
| units                     | mg.                 | mg.          |                        |  |  |  |  |  |  |  |  |
| 15                        | 202                 | 159          | 1.42                   |  |  |  |  |  |  |  |  |
| 20                        | 237                 | 172          | 1.37                   |  |  |  |  |  |  |  |  |
| 20                        | 195                 | 135          | 1.54                   |  |  |  |  |  |  |  |  |
| 20                        | 215                 | 186          | 0.67                   |  |  |  |  |  |  |  |  |
| Average                   |                     |              | 1.25 ± 0.29            |  |  |  |  |  |  |  |  |
| 7.5                       | 244                 | 199          | 2.46                   |  |  |  |  |  |  |  |  |
| 7.5                       | 314                 | 265          | 2.08                   |  |  |  |  |  |  |  |  |
| 15                        | 253                 | 208          | 1.19                   |  |  |  |  |  |  |  |  |
| 22.5                      | 325                 | 156          | 2.31                   |  |  |  |  |  |  |  |  |
| Average                   |                     |              | 2.01 ± 0.41            |  |  |  |  |  |  |  |  |

- 21 -

Three reports which implicated tyrosine in hematopoiesis further strengthened the idea that antipernicious anemia liver extracts contained some factor(s) concerned in tyrosine utilization. In 1938, Subbarow and associates (56) concluded a series of investigations on the nature of the factors in liver extracts effective in curing pernicious anemia. They suggested that the interaction of a primary and three accessory factors was necessary. The primary factor had properties which suggested a complex pyridine derivative, while one of the accessory factors was L-tyrosine. Jacobsen and Plum (57) reported that tyrosine was essential for the maturation of reticulocytes. This has been confirmed by Christensen and Plum (58), who noted that the main action of tyrosine was to enhance the action of a heat-labile factor. These reports have not, as yet, been confirmed by other investigators.

With the tyrosine-liver extract relationship revealed, it would seem pertinent to review studies concerning the nature of the factors in liver extract active in alleviation of pernicious anemia, since these may be important in tyrosine metabolism as well.

2. Multiple nature of liver factors

Pernicious anemia, according to Minot and Strauss (59), is a complicated deficiency disorder, the cause of which is

- 22 -

unknown, but may be due to a lack in the diet, or faulty absorbtion or utilization of one or more dietary factors. The disease is characterized by a macrocytic, hyperchromic anemia with the red blood cell count usually below 2,500,000 per cu. mm. As Wintrobe (60) has pointed out, this red blood cell count is not due to a failure of the cells to mature, as is the case in certain nutritional anemias, but rather is due to abnormal maturation which produces the megaloblasts found in the bone marrow in such large numbers. These megaloblast cells do not function, however, in oxygen transport. A gastro-intestinal disturbance, characterized by achlorhydria, and neural lesions later usually accompany the blood symptoms.

The classical treatment with whole or refined liver extracts produces remission of all symptoms, but must be continued or the symptoms reappear. Numerous studies have been made to determine the nature of the active material present in these liver extracts. The work of Castle and associates (61), which showed the presence of an extrinsic factor in foods, which is acted upon by an intrinsic factor, probably an enzyme found in normal gastric juice, is now classic. Cohn and associates (62), and Dakin and West (63), and others have attempted to isolate the active constituents from liver. This subject has been reviewed by Subbarow (64).

Progress in this respect, however, was limited by the difficulty of the assay procedure. This involved the

- 23 -

observation of the increase in the red blood cell count of pernicious anemia patients on administration of the various fractions. Obviously, individual variation and the difficulty in securing patients suitable for assay purposes contributed to the lack of progress.

This impasse was surmounted in 1947 by Shorb (65, 66), who found that <u>Lactobacillus lactis</u> Dorner showed growth response to refined liver extracts. An assay method was developed for the growth factor. The crystalline factor was isolated by Rickes and coworkers (67) in 1948 and the activity of the crystalline substance for growth of <u>Lactobacillus lactis</u> was discussed by Shorb (68). The compound crystallized as red needles which melted at  $300^{\circ}$ C. As little as  $3-6 \mu$ g, produced a hematopoietic response in pernicious anemia patients. This growth factor was temporarily named vitamin B<sub>12</sub>, pending identification of the compound.

Simultaneously, a group in England working under Smith (69) announced the isolation of the same or similar compound by the use of chromatographic adsorbtion techniques. The presence of cobalt, phosphorus and nitrogen in the molecule, the approximate molecular weight of 1500 and some of the physical properties were soon reported independently by both groups (69-71). Numerous reports have appeared this year giving further details of the structure and chemical properties of vitamin  $B_{12}$ . The group at Merck, which originally

- 24 -

isolated the compound, has shown the presence of basic groups in the molecule, reported optical activity and degraded the molecule with the production of 5,6-dimethylbenzimidazole as one fragment (72-74). In England, Smith and Parker (75), and Ellis and coworkers (76, 77) have reported analytical and purification details.

The clinical studies with the vitamin have established unequivocally its ability to remove all the symptoms of pernicious anemia. The original reports have been extended by Reisner and West (78), who injected pure vitamin  $B_{12}$  into 11 patients with pernicious anemia. All showed complete hematologic remission and the five with neural lesions reported improvement. This alleviation of the nervous symptoms differed sharply from the action of pteroylglutamic acid (to be reviewed in Section D) which produced only temporary increases in red blood cells (79, 80). Similar results confirming the effectiveness of the vitamin have been reported by Castle and associates (81, 82) and Spies and coworkers The usual dosages of vitamin  $B_{12}$  have ranged from 5 to (83). 10 µg. per day by injection and somewhat higher when given orally. It has been noted (82) that the oral effectiveness is increased if gastric juice from normal patients is also administered. Vitamin B12 has also been reported (83) as effective in the treatment of sprue.

These results, establishing the vital function of

- 25 -

vitamin  $B_{12}$  in blood formation, were probably only one facet of the vitamin action. Work along other lines demonstrated the importance of this vitamin in growth processes throughout the body. Thus, the probable tyrosine-vitamin relationship in blood formation may be extended in the future to the involvement of vitamin  $B_{12}$  in the general anabolic metabolism of tyrosine. The importance of this possibility, and the new fields for research opened by it, merits investigation.

Investigation of various diets for poultry had revealed the absence of important growth factors from vegetable protein diets. Byerly, Titus and Ellis (84), as far back as 1933, had reported poor hatchability and decreased chick survival on these diets. The search for the missing factor(s) was intensified by the wartime shortage of animal protein. Animal protein factor (as this was called) activity was reported in fish solubles, liver extracts, cow manure, numerous animal proteins and fermentation residues. Active work in purifying the crude factor and developing chick assay methods was carried on by Bird and coworkers (85, 86), a group headed by Elvehjem (87), a group under Hill (88), McGinnis and coworkers (89), and others.

Shortly after the isolation of vitamin  $B_{12}$  in 1948, it was reported by the Merck group (90, 91) that animal protein factor activity was associated with the compound. The suggestion was made that animal protein factor and  $B_{12}$  might be

- 26 -

identical on the basis of the high activity shown by the vitamin in promoting chick growth. Bird and coworkers (92) reported that vitamin B12 supported maximum growth of chicks on diets deficient in animal protein factor. The factor was also shown to be essential for mammalian growth. Cary and Hartman (93) reported the ability of the vitamin to substitute for their "Factor X," and it probably is related to the "Zoopherin" of Zucker and Zucker (94). Both of these factors were essential for rat growth on purified diets. The low levels of the factor required for growth made the early results equivocal in some cases, but when the dams of the experimental animals were also depleted by the use of vegetable protein or purified casein diets, the factor was found to be essential for rats by Emerson (95), for pigs by Johnson and coworkers (96), Hogan and coworkers (97) and Luecke and coworkers (98), and for mice by Bosshardt and associates (99, 100). Vitamin  $B_{12}$  promoted increased growth in all of these reports.

A large number of bacterial assays were developed. Chick and mammalian assays were complicated by the problem of depleting the assay animals. It was found by Evans and Nelson (101) that, in addition to growth, lactation required an increased amount of animal protein factor. Several authors noted that feeding of desiccated thyroid or indinated casein also increased the requirement for the factor. This latter

- 27 -

finding was made the basis for new methods of assay, using rats (102, 103), chicks (104, 105), and mice (100, 106).

In 1949, when certain natural sources of these various factors were compared on the basis of their antipernicious anemia, microbiological and animal protein factor activity, certain discrepancies became apparent. Some of these natural products had, for example, more animal protein factor activity than would be predicted from their  $B_{12}$  content (based on microbiological assay). Elvehjem and coworkers (107) confirmed this and showed that the ethyl alcohol extract of liver, discarded in the preparation of antipernicious anemia extracts, had an extremely high chick growth potency. Stokstad and coworkers (108) reported that the maximum growth obtained by chicks on vitamin B12-supplemented diets could be increased by the addition of other liver fractions. Cunha and coworkers (109) reported that the growth of pigs on cornpeanut meal rations was increased by a Fuller's earth concentrate of vitamin B12, but that greater maximum growth was obtained when animal protein factor from fermentation residues was used as supplement. A number of authors reported the separation of highly refined antipernicious anemia extracts by paper chromatography and electrolytic methods into as many as six components. Snook and associates (77) discussed the analyses of vitamin B12. The Merck group (73) had reported a cobalt: phosphorus ratio of 1:1, while the

- 28 -

English group's compound (71) had a 1:3 ratic. These discrepancies seemed to indicate that different forms of the vitamin, possibly produced by the isolation processes, existed and had biological activity.

Stokstad and coworkers (110) have reported that chromatography of <u>Streptomyces aureofaciens</u> fermentation residues yielded two crystalline fractions. Both showed biological activity by chick and microbiological assay. The absorbtion spectra of these two compounds differed, and the spectrum of one was similar to that of vitamin  $B_{12}$ . The authors named the other compound vitamin  $B_{12b}$ . Vitamin  $B_{12a}$  had previously been described (72) as a hydrogenation product of the vitamin.

Finally, two English reports by Cuthbertson and associates (111) and Shaw (112) revealed discrepancies between clinical antipernicious anemia and vitamin  $B_{12}$  (by microbiological assay) activity of liver extracts. They inferred that the form or forms of the vitamin present in liver extracts were more active clinically than would be expected on the basis of their vitamin  $B_{12}$  content.

At the present time, therefore, it seems probable that more than one chemical compound exists with vitamin  $B_{12}$ activity. The conjugation of the vitamin with unknown substances probably differs depending on the source. The activity of these various forms then would depend on the species used for assay and the criterion used, as growth,

- 29 -

blood formation, and so forth. The elucidation of the structure of the vitamin should clarify many of these questions.

Several attempts have been made to assign these  $B_{12}$  compounds a specific function in growth. One of the earliest ideas was advanced by Shive and coworkers (113, 114) and by Wright and associates (115). Inhibition studies on <u>Lactobacillus lactis</u> had shown that the nucleoside, thymidine, could replace the requirement of this organism for vitamin  $B_{12}$ . The data supported the conception of vitamin  $B_{12}$  as functioning in the biosynthesis of the nucleoside. However, more recently it has been shown by numerous authors that purines and other nucleosides essential for bacterial growth are spared by the vitamin and that the relationship depends on the bacterial species being tested.

A relationship between transmethylation and the vitamin has been reported by Salmon (116), who showed that the presence of vitamin  $B_{12}$  in the diet of chicks and rats reduced the requirement for choline. Similar data have been presented by Norris and coworkers (117), while Cunha and associates (109) have reported that the enhanced growth of pigs on cornpeanut meal rations, which was produced by methionine supplementation, could also be produced by animal protein factor. When the animal protein factor was present, extra methionine had no effect on growth.

Cary and coworkers (118) concluded that vitamin  $B_{12}$ 

- 30 -

played a fundamental role in the capacity of mammals to utilize protein. Their data was concerned with the growth increases of vitamin  $B_{12}$ -supplemented rats over control animals, as the protein in the diet was increased from 25 to 65%. As the protein content of the diet was increased, the growthpromoting effect of the vitamin supplementation increased. This fact was cited as evidence for their conclusions.

The large number of reports cited in this section, all appearing since the isolation of vitamin  $B_{1,2}$  in 1948, are evidence of the importance attached to this factor. The elucidation of the structure of the vitamin, and of the various forms which occur naturally, has not yet been accomplished. However, the almost universal participation of these factors in growth processes and the specific function of the vitamin in blood formation seem to have been shown conclusively. The activity of antipernicious anemia liver extracts in tyrosine metabolism, which has been demonstrated in the guinea pig, may possibly be related to some function of tyrosine in blood formation. However, the combined action of pteroylglutamic acid and liver extracts in blood formation has now been extended to other growth processes, and it seems probable that the tyrosine-liver extract relationship as well is not confined to hematopoiesis. The action of pteroylglutamic acid in tyrosine metabolism and the more complex interrelationships which have been reported between this vitamin and

- 31 -

other accessory factors will be discussed in the following section.

D. Folic Acid and Tyrosine Metabolism

The isolation of pteroylglutamic acid, also called folic acid, and the various conjugates of the vitamin several years ago resulted in an intensified study of the various functions of these compounds. This situation is comparable to the widespread interest today in vitamin  $B_{12}$ . The importance of folic acid in hematopoiesis and its effectiveness in curing certain anemias was soon demonstrated. The close relationship of pteroylglutamic acid and the liver principle in blood formation and their apparently synergistic action in curing certain anemias was demonstrated. Folic acid was found to improve the blood picture in pernicious anemia. Stokstad and Jukes (119) reviewed this subject in 1948.

These facts influenced Rodney, Swendseid and Swanson (120) to investigate the influence of pteroylglutamic acid on tyrosine metabolism. Rats were made deficient in the vitamin by feeding sulfasuxidine, and the ability of liver homogenates from these animals to oxidize tyrosine was investigated in the Warburg apparatus. Oxygen uptake by the deficient livers was lower than normal controls and the addition of pteroylglutamic acid resulted in an increased oxidation. In 1949, the same authors (121) repeated these experiments on folic

- 32 -

acid-deficient rats with some modifications. The in vitro addition of crystalline folic acid partially restored the oxygen uptake of deficient liver brei, as had previously been reported. Vitamin C and liver extract had no effect. The addition of a folic acid antagonist, 4-aminopteroylglutamic acid, in vitro had no effect on tyrosine oxidation. Livers from animals fed this antagonist, however, did show a decreased oxidation of tyrosine. Contrary to the expected result, the addition of folic acid to the system in this instance had no effect. However, when folic acid or liver extracts were included in the diet along with the antagonist, the tyrosine oxidation in vitro was normal. The function of pteroylglutamic acid in tyrosine oxidation seems to be complex, therefore, and closely connected with the action of factors in liver extract.

The earlier experiments of Swendseid and coworkers led Woodruff and Darby (122, 123) to investigate the effect of pteroylglutamic acid on the excretion of tyrosine metabolites by the vitamin C-deficient guines pig. They found that this vitamin abolished the excretion of these metabolites as effectively as did vitamin C.

In the first series of experiments the vitamin was administered orally. In this case, 15 mg. per day for three days was required to reduce the tyrosyl (phenolic) value to 5% of the administered tyrosine. Later it was shown that

- 33 -

lowered excretory values could be maintained for as long as 20 days when the animals were fed a scorbutigenic diet plus 5% L-tyrosine and daily injections of 5 mg. of folic acid were administered. The four groups analyzed consisted of two animals each on the following diets: experimental, experimental plus folic acid, experimental plus vitamin C, and experimental plus both vitamins. The average daily tyrosyl values over the 20-day period for these groups were 37.3, 6.6, 5.2, and 4.6%, respectively.

Some criticism may be made of this long-time experiment, since the food intake (and consequently the tyrosine intake) of the one animal reported in detail (folic acid group) fell to zero several times during the experiment. In addition to pteroylglutamic acid, the triglutamate, but not the diglutamate, caused a decreased tyrosine metabolite excretion.

These authors also reported that daily intramuscular injections of 5 U. S. P. units of liver extract produced no change in metabolite excretion. This report is contrary to that of Sealock and Lepow (55). However, the conditions of the two experiments differed considerably. The basal diet was different, the pre-injection level of metabolite excretion in Woodruff and Darby's experiments was considerably lower, their dosage was at the extreme low end of the effective range as reported by Sealock, and they tabulated the average excretion level over a four-day period, while the excretion

- 34 -

during the 24-hour period following the injection has been used by Sealock as the criterion of effectiveness. This criterion was used because the effect of the injection of liver extracts disappeared after the first 24-hour period (124).

Recently, Govan and Gordon (125) have reported that the administration of 10-30 mg. of folic acid removed the abnormal tyrosyl metabolites excreted by premature infants on cow's milk diets. However, the variability of response, which had previously been noted when liver extract was used (47), was again reported. Data on 10 infants was given. Four of these responded to folic acid treatment, while the others did not. Five of these others, however, did respond to vitamin C therapy.

The results cited in this section definitely implicate folic acid in tyrosine metabolism. Its action resembles that of vitamin C in the amounts used, the duration and intensity of the tyrosine metabolite decreases produced, and the demonstration of an <u>in vitro</u> effect on tyrosine oxidation. On the other hand, reports in fields other than tyrosine metabolism, stress the close relationship of folic acid to liver extracts in blood formation and growth processes. Some of the more pertinent relationships among these three factors will be cited in the following paragraphs. No information is available, however, as to what connection these factors have with one another in tyrosine metabolism. If folic acid and vitamin C are concerned with a catabolic pathway of the amino acid, do they act at different stages of the same one, or do they act on two different pathways? Do the liver factor(s) act in an anabolic capacity? If so, what anabolic pathway of tyrosine is affected? These questions have not yet been answered.

Wintrobe (126) has shown that a folic acid deficiency in pigs resulted in a macrocytic anemia which closely resembled that found in pernicious anemia. Even the megaloblastic bone marrow was evident. The primary cure for this nutritional anemia was the administration of folic acid, although liver extracts and vitamin  $B_{12}$  had some curative effect. On the other hand, liver extracts seem to be the primary agents in the cure of pernicious anemia, though folic acid may alleviate the anemia. Bethell (127) has reported one case of pernicious anemia where a folic acid antagonist, 4-aminopteroylglutamic acid, blocked the usual response to the administration of vitamin  $B_{12}$ . This relationship appears to be similar to that found by Swendseid (121).

Very recently, Bennett (128) has reported experiments with rats on synthetic diets which she has interpreted to indicate a vitamin  $B_{12}$ -folic acid function in the utilization of homocystime. These rats showed normal rates of growth on a synthetic diet (amino acid mixture) containing no known methyl donors, and homocystine as the only sulphur-containing amino acid. However, the addition of sulfasuxidine to the diet resulted in poor growth. Addition of biotin improved growth slightly, and high levels of folic acid, in addition to biotin, restored growth to normal in some animals. Animals which did not respond to these two vitamins, did show good growth when "Liver Extract Lilly" was added also. Growth rates reported for these various groups in gm. per day were: basal, 1.5; basal plus 2% sulfasuxidine, 0.3; basal plus biotin and folic acid, 1.3; basal plus biotin, folic acid and liver extract (growth of this group without liver extract was 0.0), 1.3. The author interpreted these results to indicate that folic acid and a factor found in liver extracts were required for homocystine utilization under the experimental conditions. Differences in storage levels of other B vitamins, of which vitamin  $B_{12}$  was probably the most important, accounted for the variability in the response to folic acid alone.

Elvehjem and coworkers (129) have studied the action of different factors on niacin-deficient dogs. These dogs lost weight and developed a macrocytic anemia. Finally, they ceased to respond to niacin supplementation. At this stage, folic acid produced hematopoietic responses, but the greatest gains in blood formation and weight were produced by administration of purified liver extracts in addition to these other factors. The same group (130) has studied phenylhydrazineinduced anemia in folic acid-deficient chicks. Here again, folic acid produced some improvement, but the further addition of antipernicious anemia extracts was required for most rapid return to normal blood levels. Recently, the activity of various enzymes (131) from these folic acid-deficient chicks was studied. The effect of folic acid and vitamin  $B_{12}$ additions <u>in vitro</u> to these systems was reported, but no definite conclusions were drawn.

Day and coworkers (132) have reported that the growth depression produced by addition of 10% glycine to the diet of rats is prevented by inclusion of folic acid in the diet, though vitamin C and liver extract also had some effect.

Johnson and Dana (133) fed rats a folic acid-deficient diet, plus sulfasuxidine. The addition of vitamin C to this diet caused a significant weight gain and disappearance of hemorrhages. The further addition of folic acid produced a significant increase in reticulocytes. Elvehjem and coworkers (134) noted that vitamin C aided chicks on a folic acid-deficient diet. The hemoglobin levels were increased in this case and growth was affected by folic acid only.

- 38 -

#### E. Other Dictary Factors

- 39 -

1. Amino acids and other vitamins

A number of papers have appeared in which defects in tyrosine metabolism have been noted when dietary factors other than those previously discussed were omitted. Experimental alcaptonuria has been produced in rats by feeding large amounts of tyrosine or phenylalanine by Butts and coworkers (28), Papageorge and Lewis (40), Abbott and Salmon (135), and Lanyar (136); and in mice by Lanyar (137).

In 1945, Neuberger and associates (138) showed that the excretion of homogentisic acid by the rat receiving extra tyrosine was dependent on the cystine and methionine intake. Small amounts of tyrosine could produce the metabolic defect when these amino acids were absent from the diet. It was later shown (139) that albino rats developed the defect more easily than pigmented strains, but that when the protein intake was low, or essential amino acids were missing from the diet, both strains failed to metabolize tyrosine completely. Thus the primary defect in this experimental alcaptonuria, it was suggested, was an overloading of the catabolic pathways by extra tyrosine, which was accentuated when the anabolic pathways were blocked by lack of essential amino acids. As a result, the intermediate metabolic product of tyrosine oxidation, homogentisic acid, appeared in the urine. Several authors have reported toxic effects when large doses of tyrosine were fed to very young rats. Martin and coworkers (140, 141) noted skin lesions and hyperglycemia under these conditions. The primary defect seemed to be a riboflavin deficiency, but the addition of cystine or glycine to the diet decreased the symptoms. Marnay (142) has reported similar effects when tyrosine was fed at a level of 5% in the diet, in addition to that found in the 19% casein which was the protein source. He also reported that cystine had a curative action. Thus it is possible that cystine has a more specific relationship to tyrosine metabolism than the work of Neuberger would indicate.

#### 2. Purified diets for guinea pigs

The multiplicity of factors which had been reported to be of importance in tyrosine metabolism indicated the use of a purified diet, the composition of which was known, for any experimental work concerned with tyrosine utilization. Attempts to produce such a diet had been initiated soon after the guinea pig was introduced as a laboratory animal. However, it was not until a few months ago that a diet was devised which would permit growth equal to that produced on natural diets. Woolley and coworkers (143, 144) found that when three factors were added to their casein-sucrose ration, a growth rate of 4 gm. per day was obtained. These factors were identified as folic acid, some constituent of liver extracts, and a bulk factor which was supplied by cellulose and protein. King and associates (145) developed a ration which supported daily growth of 4.4 gm. for 100 days. At least two nutrients of vitamin nature, one found in crude casein and the other in rice polishing concentrates, were needed.

Elvehjem and Hart (146) reported results using a sucrosecase in ration, which when supplemented with various crude materials, supported growth equal to that on a commercial ration. These supplements included Cellu flour, beet pulp and gum arabic at the 30% level. The gum arabic was best, but an hydrolyzate prepared from it had no growth-promoting action. Presumably some bulk factor, which previous authors also had noted as being necessary, was furnished. A ration containing sucrose, casein, vitamins, salts and 15% gum arabic produced growth of 5.1 gm. per day. The addition of alfalfa leaf meal improved this diet so that normal growth of 7-8 gm. per day was obtained. Astonishingly, however, the ash of this last supplement proved as effective as the meal. The authors hypothesized that the ash furnished a high level of potassium, which was needed by the guinea pig. The final results (147) confirmed this idea. A diet containing sucrose, 30% casein, 15% gum arabic, vitamins, salts, and soybean oil, and supplemented with 2.5% potassium acetate and 0.5% magnesium oxide supported normal growth during the experimental period.

- 41 -

#### F. Isotope Studies of Tyrosine Metabolism

In 1939, Schoenheimer and his collaborators (148-151) instituted their studies of protein metabolism which eventually resulted in the present concept of the dynamic state of body constituents. For these studies they used amino acids labelled with isotopic nitrogen. They discussed theoretical considerations involved in the use of  $N^{15}$  and methods of analysis and demonstrated that the amino group of amino acids did not exchange with the surrounding nitrogenous constituents unless chemical reaction took place. After these preliminary papers, the authors proceeded to synthesize amino acids with  $N^{15}$  in the amino group and feed these to rats.

Their tyrosine experiment (151) involved the addition of small amounts of DL-tyrosine (containing 2.04 atoms % excess  $N^{15}$ ) to the diet for 10 days. At the end of the 10-day period, when the animal was killed, 1.86 gm. of the isotopic tyrosine and 0.93 gm. of the normal tyrosine in the casein had been consumed. Analyses of urinary constituents, liver, blood and carcass fractions were made.

In general, the isotopic nitrogen of the tissues was found mainly in protein and, apart from tyrosine, was found in four different fractions: 1) in the  $\propto$  - amino group of the dicarboxylic amino acids; 2) in histidine from the liver; 3) in the "potential urea" portion of arginine; 4) in the

- 42 -

protein "amide nitrogen" (liberated as ammonia during proteolysis). The only fraction isolated from protein which contained no isotopic nitrogen was lysine. All of these protein fractions only accounted for a small portion of the total isotope in the protein, so other fractions not analyzed evidently contained considerable amounts of the isotopic nitrogen.

Table III shows a summary (by the writer) of the analyses for which the "% yield" could be calculated. No quantitative recovery was reported for those fractions not listed in the table, and Schoenheimer's conclusions were drawn from a consideration of the determination of "atoms % N<sup>15</sup> excess" only in these cases. The calculated "% yield" in Table III is based on the isotopic DL-tyrosine consumed.

Despite the fact that the animal remained in nitrogen equilibrium throughout the experimental period, Schoenheimer noted that about 48% of the dietary tyrosine nitrogen remained in the body. This was the first demonstration of the exchange between food and body constituents, which was later expanded into the theory of the dynamic state of body constituents.

It should be noted that all these results were calculated on the basis of the racemic amino acid fed. Undoubtedly, the metabolism of the D-isomer differs from that of the natural form in some respects and this obscures more quantitative interpretation of these results. The fate of a large

- 43 -

## Table III

# Isotope Recovery After Feeding DL-Tyrosine Containing N<sup>15</sup>

| Source  | Substance                    | N <sup>15</sup><br>excess | Total N            | N <sup>15</sup><br>excess | % yield |
|---------|------------------------------|---------------------------|--------------------|---------------------------|---------|
|         |                              | atom %                    | mg.                | mg.                       |         |
| Diet    | Total tyrosine<br>consumed   | 1.36                      | 213.0              | 2.90                      |         |
| Liver   | Non-protein N                | 0.038                     | 16.5               | 0.0063                    | 0.2     |
|         | Total protein                | 0.039                     | 224.0              | 0.087                     | 3.0     |
|         | Tyrosine                     | 0.316                     | 5.9 <sup>1</sup>   | 0.018                     | 0.6     |
|         | Amide N                      | 0.044                     | 10.7               | 0.0047                    | 0.2     |
| Carcass | Non-protein N                | 0.015                     | 947.0              | 0.142                     | 4.9     |
|         | Total protein                | 0.012                     | 8900.0             | 1.06                      | 40.0    |
|         | Tyrosine                     | 0.100                     | 213.0 <sup>1</sup> | 0.21                      | 5.6     |
|         | Amide N                      | 0.012                     | 383.0              | 0.046                     | 1.6     |
| Blood   | Protein from<br>plasma       | 0.029                     | 47.5               | 0.014                     | 0.5     |
|         | Non-protein N<br>from plasma | 0.066                     | 1.8                | 0.001                     | 0.03    |
| Urine   | Total N first<br>9 days      | 0.077                     | 1950.0             | 1.50                      | 51.8    |
|         | Total N last day             | 0.067                     | 167.5              | 0.11                      | 3.8     |
|         | Urea last<br>day             | 0.067                     | 140.0              | 0.094                     | 3.2     |
|         | Ammonia last<br>day          | 0.197                     | 3.0                | 0.006                     | 0.2     |
|         | Total r                      | ecovery                   |                    |                           | 104.2   |
| 1       | 1                            |                           |                    |                           |         |

<sup>1</sup>Calculated from analysis on another animal.

portion of the isotopic nitrogen in the protein has not been determined, and further analyses should yield additional information concerning the metabolism of this amino acid.

The experiment cited above is the only reported one in which isotopic nitrogen was used to mark the tyrosine mole-Studies with marked tyrosine, in which the various cule. dietary factors implicated in the metabolism of the amino acid are varied for the purpose of determining their site of action and function, should yield important information. The most logical start for such a series of experiments would utilize isotopic nitrogen. since it is quite possible that one of these vitamin factors may function in the removal of the amino group from the molecule. Also, for in vivo experiments isotopic nitrogen is more easily traced than deuterium or isotopic carbon since the dilution factor in the body is many times smaller. No studies such as these have been reported.

Radioactive carbon  $(C^{14})$  and heavy carbon  $(C^{13})$ , however, have been incorporated in the tyrosine molecule for the purpose of studying some particular catabolic pathway. These investigations have been metabolic turnover studies <u>in vivo</u>, utilizing racemic tyrosine, thus making interpretation difficult; others have been <u>in vitro</u> investigations of some particular catabolic pathway.

Winnick, Friedberg and Greenberg (152) fed tyrosine

- 45 -


labelled with  $C^{14}$  in the  $\beta$ -position of the sidechain to a normal and a tumor-bearing rat. The carbon chain of the tyrosine, in contrast to the amino group, did not contribute significantly to the formation of other amino acids. Approximately 30% of the administered dose was found in protein, all as tyrosine. Intestinal mucosa had the highest  $C^{14}$ concentration, followed by kidney and blood plasma. The liver had some  $C^{14}$ , but very little was found in adrenals or thyroid. These findings may be related to the short time factor to some extent, since the dose was injected into the jugular vein and the animal killed six hours later.

Of the 1.0 mg. of tyrosine administered, approximately 30% was found in protein and 27% in the urine. The rest has not been accounted for by the analyses. Tyrosine, urea, acetoacetic acid, ketones, hippuric acid and creatinine accounted for 50% of the urinary radioactivity. The authors believed that the following reactions accounted for the radioactivity in hippuric acid and creatinine:

tyrosine  $\longrightarrow$  acetoacetic acid  $\longrightarrow$  acetic acid  $\longrightarrow$  glycine.


Reid and Jones (153) reported a similar study of the administration of radioactive tyrosine to mice bearing a melanosarcoma. After 72 hours, 30% of the administered dose appeared in the respiratory carbon dioxide, 40% in the urine and feces, and 30% in the carcass. Radioactivity was found in every tissue of the body, and the highest activities, in general, were found to confirm the findings previously described. However, the adrenals and thyroid also showed high activity.

Weinhouse and Millington (154) incubated L-tyrosine, containing  $C^{14}$  in the  $\beta$ -position of the sidechain, with rat liver slices. Acetoacetate was isolated and degradation studies located almost all of the radioactivity in the  $\alpha$ -carbon atom. The carboxyl group showed little radioactivity. The authors concluded that their findings were in accord with the scheme:



Gurin and coworkers (155, 156) have reported confirmatory experiments using labelled phenylalanine. The DL-form was used with  $C^{14}$  in the carboxyl group and the  $\propto$ -position of the sidechain. Incubation with rat liver slices, and isolation of the acetoacetic acid produced, showed the presence of  $C^{14}$  in the carboxyl group only. The respiratory carbon dioxide also contained some isotope, showing that the original carboxyl group of the phenylalanine had been eliminated. The labelled amino acid was also fed to phlorizindiabetic rats, but the excreted radioactivity was quite low.

In another experiment, phenylalanine ring-labelled in the 1,3 and 5 positions was incubated as previously and acetoacetate was isolated. Most of the radioactivity was found in the methyl carbon atom of the acetoacetate. The only mechanism which would explain this finding would involve a shift in the side chain as shown below:



This scheme is in accord with the previously postulated mechanisms of Neuberger (21) and Neubauer (5), which involve quinol intermediates.

In November of 1949, Lerner (157) extended these studies in an effort to determine the fate of the other portions of the tyrosine molecule. For this purpose, L-phenylalanine was synthesized with  $C^{14}$  in every position of the ring and  $C^{13}$  in the  $\alpha$ -position of the sidechain. Also, L-tyrosine with  $C^{14}$ in the  $\beta$ -position of the sidechain was used. These compounds were incubated with rat liver slices. The acetoacetic acid isolated from phenylalanine incubation contained  $C^{14}$  in the  $\beta$ -and  $\delta$ -positions and  $C^{13}$  in the carboxyl group. This confirmed the work of Gurin, cited above, and indicated that the acetoacetic acid was formed from two ring carbons and the  $\infty$ -and  $\beta$ -carbons of the phenylalanine side chain split off as an intact molecule.

The author also isolated malic acid with C<sup>14</sup> in every position. This compound, as well as acetoacetic acid, was a major component of the oxidation, since 14.2% of the starting radioactivity was recovered as malic acid and 7.3% as carbon dioxide derived from malic acid. This compound was formed from the four ring carbon atoms which were not involved in acetoacetic acid formation. The studies with labelled tyrosine confirmed those with phenylalanine. Cleavage of homogentisic acid, as shown below, could yield these two products:

OH

#### III. EXPERIMENTAL

#### A. Effects of Concentrated Liver Extracts

1. Methods

The guinea pigs used for these experiments were obtained from commercial dealers and maintained in stock cages on Purina Rabbit Chow, complete ration, supplemented with carrots and cabbage. Later, some animals were kept on Rockland Guinea Pig Ration (vitamin C-fortified). Animals weighing from 250 to 500 gm. were used for experiments. For the metabolic experiments they were housed in individual wire mesh cages supported in large funnels. Feces and food particles were caught in fine mesh screening underneath the cage, while the urine ran into a collecting bottle. This bottle contained 10 ml. of 2.0 N. hydrochleric acid.

Only male animals were used for experiment. These were fed a basal diet which contained insignificant amounts of vitamin C. The basal diet was prepared by grinding Purina Rabbit Chow to a fine powder and spreading in a thin layer. Exposure to the air in this manner for five or more days destroyed the small amounts of the vitamin originally present. After two to three days on this basal diet, the animals were fed daily supplements of 200 mg. per 100 gm. of body weight

- 50 -

of L-tyrosine. L-Tyrosine, purchased from Merck and Company, was fed as a 10% mixture with the basal diet. In addition to the tyrosine supplement, the food pans always contained basal diet, and more was added when the animals had consumed the supplement. A few experiments in which the animals did not eat all of the supplement were discarded. The guinea pigs were weighed daily while on experiment. At the start of each 24-hour period approximately 0.9 gm. of Squibb or Mead Brewers' Yeast was sprinkled on top of the diet mixture. All animals were fed 1.0 ml. of cod liver oil per week by pipette. A supply of fresh water was always available.

At the end of each 24-hour period, the splattered urine was washed from the funnel into the collecting bottles. The urine samples plus washings were filtered through No. 4 Whatman filter paper into 100 ml. graduated cylinders and diluted to that volume with distilled water. Analyses were done immediately on aliquots of this or of a 1:20 dilution.

Analyses for keto acid were done with the 2,4-dinitrophenylhydrazine reagent according to the method of Penrose and Quastel (158), as modified in this laboratory (124). Total tyrosyl values (phenol) were determined by the method of Folin and Ciocalteu (159), as modified in this laboratory (124). This method depends on the quantitative development of a blue color when phosphotungstic-phosphomolybdic acid is added to a phenol-containing solution. All readings were

- 51 -

made on the Klett-Summerson photoelectric colorimeter with the appropriate filter and standard. Due to the instability of <u>p</u>-hydroxyphenylpyruvic acid, it could not be used as a primary standard for the keto acid determination. Instead, the colorimeter was calibrated with a freshly-prepared solution of p-hydroxyphenylpyruvic acid.

The experimental procedure followed, unless otherwise indicated, was to feed the tyrosine supplement and analyze at the end of each 24-hour period until the keto acid excretion was 30% or more of the administered extra tyrosine. The various vitamin supplements were then given at the start of the 24-hour period and analyses continued usually for several days following vitamin supplementation. Vitamin C was given by mouth as a water suspension, liver extract was injected intraperitoneally and folic acid injected subcutaneously, unless otherwise noted.

#### 2. Analysis of assay procedure

The first series of injections of liver extract were preliminary in nature, and made for the purpose of studying the variation when the same dose was injected into different animals and to follow the proportionality of response to administered dose. Two preparations were tested. These were high-potency experimental extracts identified as Armour 1080 and 1103. The antipernicious anemia potency of these extracts was approximately 20 U. S. P. units per ml., although they were prepared from different liver batches. A few injections were made subcutaneously, but later the intraperitoneal route was adopted, as it was felt more rapid absorbtion and hence greater effectiveness was obtained.

A typical experiment is shown in Figure 1. The prompt decrease in both keto acid and tyrosyl values upon administration of liver extract can be seen. The level of metabolites is plotted as per cent of theoretical yield, based on the amount of extra tyrosine fed. The changes in both tyrosyl and keto acid values parallel each other approximately, as was usually the case. The rapid increase in metabolite excretion on the second day after injection was also typical.

The results of the complete series of injections are reported in Table IV. Only keto acid values are given, since the tyrosyl changes paralleled these so closely. In some cases, more than one injection was made, but the effect of these later injections was very small (as will be shown). Therefore, only the excretion values in the 24-hour period following the first injection are reported. When a guinea pig was used more than once, it was only after several weeks on the stock diet prior to the second experiment.

- 53 -




FIG. I Excretion of keto acid (solid columns) and tyrosyl metabolite calculated as tyrosine (clear columns). Arrow indicates liver extract injection.

- 54 -

Various calculations may be made to express the change in the level of metabolite excretion. The "Decrease" in Table IV is the simple difference between the keto acid levels, expressed as per cent of the theoretical yield, before and after injection. This expression will be used in most of the tables and is represented by the figure 5.9 in Column 7 of Table IV. However, the magnitude of this change in relation to the pre-injection level may be expressed by dividing this figure by the keto acid level (%) prior to injection and multiplying by 100. This "Percentage Decrease," in the example cited, would be equal to 5.9 divided by 50.3 multiplied by 100, or 11.7%.

The results given in Table IV show that although the two preparations had similar antipernicious anemia activity, their ability to decrease metabolite excretion was quite different. In addition, the variability within each group was high, particularly in the case of the less effective extract. The proportionality of decrease to dose was poor, since the smaller injections produced a greater response per 0.1 ml. injected. This may have contributed to the variability within the group and accordingly a series of experiments was designed to test the effect of injection volume on response.

- 55 -

## Table IV

## Keto Acid Excretion Before and After Liver Extract Injection

| G.         |     | Ŭ   | rinary       | excret | ion         |                  | In-         | De-<br>crease  |
|------------|-----|-----|--------------|--------|-------------|------------------|-------------|----------------|
| pig<br>no. | Wt. |     | acid<br>fore |        | acid<br>ter | De-<br>crease    | jec-<br>ted | per<br>0.1 ml. |
|            | gm. | mg. | K            | mg.    | %           | ×                | ml.         | %              |
|            |     |     |              |        |             | A                | mour 10     | 080            |
| 3          | 380 | 382 | 50.3         | 337    | 44.4        | 5.9 <sup>1</sup> | 0.1         | 5.9            |
| 4          | 340 | 404 | 59.5         | 350    | 51.5        | 8.0              | 0.2         | 4.0            |
| 8          | 395 | 296 | 37.5         | 169    | 21.4        | 16.1             | 1.0         | 1.6            |
| 4          | 350 | 386 | 56.8         | 222    | 31.7        | 25.1             | 1.0         | 2.5            |
| Aver       | age |     |              |        |             |                  |             | 3.5            |
|            |     |     |              |        |             | A                | mour 11     | LO <b>3</b>    |
| 8          | 440 | 304 | 34.5         | 291    | 32.4        | 2.1              | 0.8         | 0.3            |
| 4          | 400 | 217 | 27.2         | 362    | 44.2        | +17.02           | 0.8         | +2.1           |
| 6          | 460 | 320 | 34.8         | 385    | 41.8        | + 7.0            | 0.8         | +0.9           |
| 7          | 450 | 260 | 28.9         | 195    | 21.7        | 7.2              | 0.8         | 0.9            |
| 10         | 450 | 271 | 30.2         | 108    | 12.0        | 18.2             | 0.8         | 2.3            |
| Aver       | age |     |              |        |             |                  |             | 0.1            |

<sup>1</sup>Difference between keto acid level (%) before and after injection.

<sup>2</sup>Plus signs indicate an increased urinary excretion.

- 56 -

The effect of injection volume on metabolite excretion may be observed in Table V. All of these injections consisted of 0.5 ml. of Lilly LS-1002-20. This preparation was a commercial antipernicious anemia extract containing 20 units per ml. Previous work in this laboratory (124) had shown this extract to have good activity in these guinea pig experiments. Only keto acid values are reported, since tyrosyl values paralleled these closely.

The relative ineffectiveness of this preparation, in general, may be seen. Since the same extract had previously given good results, evidently there was a loss in potency during storage of this highly purified preparation. The age of the extract, even though stored in the cold, is thus a factor which contributes to the variability of results.

The injection volumes seemed to have no definite effect on the response, except that the 5.0 ml. injections gave good decreases in two instances. However, this large injection volume resulted in poor food consumption. It was concluded that 1 to 2 ml. of undiluted 20 unit extract would be best for future work.

- 57 -

## Table V

## Keto Acid Excretion Before and After Liver Extract Injection

| G.         |     |             | Urinary      | excretio    | n            |                    | Injec-          |
|------------|-----|-------------|--------------|-------------|--------------|--------------------|-----------------|
| pig<br>no. | Wt. | Keto<br>bef | acid<br>'ore | Keto<br>aft |              | De-<br>crease      | tion1<br>volume |
|            | gm. | mg.         | K            | mg.         | *            | Ж                  | ml.             |
| 15         | 300 | 258         | 43.2         | 280         | 45.2         | + 2.0 <sup>2</sup> | 0.5             |
| 20         | 260 | 236         | 45.4         | 244         | 45.2         | 0.2                | 0.5             |
| 23         | 300 | 218         | 36.4         | 233         | 38.8         | + 2.4              | 0.5             |
| 27         | 420 | 252         | 30.0         | 459         | 53.4         | +23.4              | 0.5             |
| 17         | 300 | 172         | 28.6         | 228         | 39.3         | +10.7              | 1.0             |
| 18         | 330 | 217         | 32.9         | 98.5        | 15.4         | 17.5               | 1.5             |
| 16         | 340 | 223         | 36.0         | 396         | 58.3         | +22.3              | 2.0             |
| 19         | 360 | 332         | 46.2         | 310         | 45 <b>.6</b> | 0.6                | 5.0             |
| 24         | 430 | 244         | 28.4         | 165         | 19.2         | 9.2                | 5.0             |
| 22         | 390 | 322         | 41.3         | 324         | 42.7         | + 1.4              | 5.0             |
| 28         | 390 | 203         | 26.1         | 95.5        | 12.6         | 13.5               | 5.0             |

<sup>1</sup>All of these injections consisted of 0.5 ml. of Lilly LS-1002-20 diluted to the indicated volume.

2<sub>Plus</sub> sign indicates an increased urinary excretion.

While a considerable difference in response from animal to animal was still observed when more potent extracts were used, some decrease in metabolite excretion was always evident. Table VI lists the results obtained with freshly purchased commercial extracts of similar potency to those previously used. Two preparations, Eli Lilly No. 377 and Reticulogen No. 360, assayed at a minimum of 15 units per ml. were used. The average "Percentage decrease" shown in Table VI represents a drop in keto acid excretion of more than half. Tyrosyl values paralleled these changes closely and are therefore not reported.

It may be pertinent at this point to show the excretory pattern of an animal receiving extra tyrosine but no other supplement. Although numerous reports (see Historical) have appeared indicating that metabolite excretion remains high in the absence of vitamin C or other active supplement, one such control is shown in Figure 2. The excretory values remained high, particularly when compared with those recorded in Table VI after liver extract injection. The average of each two-day period is recorded, rather than individual days, in order to show a longer period on the graph. This animal was maintained on the C-free basal diet plus extra tyrosine for 26 days. While the excretory values fluctuated somewhat toward the end of the experiment, the keto acid values never dropped below 30%. These fluctuations can be definitely

- 59 -

#### Table VI

## Keto Acid Excretion Before and After Liver Extract Injection

| G.         |       | Urinary excretion |              |             |      |               | Per-                        |                            |  |
|------------|-------|-------------------|--------------|-------------|------|---------------|-----------------------------|----------------------------|--|
| pig<br>no. | Wt.   |                   | acid<br>fore | Keto<br>aft |      | De-<br>crease | cent-<br>age de-<br>creasel | In-<br>jected <sup>2</sup> |  |
|            | gm.   | mg.               | %            | mg.         | ж    | %             |                             | ml.                        |  |
| 26         | 350   | 270               | 38.5         | 131         | 18.2 | 20.3          | 52.9                        | 1.0                        |  |
| 22         | 450   | 343               | 38.2         | 92.5        | 10.0 | 28.2          | 73.9                        | 1.0                        |  |
| 35         | 530 - | 304               | 28.6         | 196         | 18.5 | 10.1          | 36.6                        | 1.0                        |  |
| 38         | 330   | 331               | 50.2         | 100         | 17.3 | 32.9          | 65.5                        | 1.0                        |  |

Average

57.2

<sup>1</sup>"Decrease" divided by "Keto acid before (%)" x 100.

<sup>2</sup>The first 3 injections are Lilly No. 377 and the last is Reticulogen No. 360.

- 60 -




FIG. 2 EXCRETION OF KETO ACID (SOLID COLUMNS) AND TYROSYL METABOLITE CALCULATED AS TYROSINE (CLEAR COLUMNS). CONTROL ANIMAL, AVERAGE OF 2 DAYS IN EACH COLUMN.

attributed to the variation in food consumption which began to appear when the vitamin C deficiency became acute. The usual experiment lasted less than 10 days. It should be noted that, in addition to the factor of poor food consumption, if the room temperature accidentally dropped to freezing or below for a period of several hours, the metabolite excretion would decrease. Such experiments were discarded.

Following the rather sharp decreases obtained with the 1.0 ml. injections shown in Table VI, it was felt that even greater decreases in metabolite excretion could be obtained. Vitamin C and folic acid completely abolish metabolite excretion if the dosage is large enough. However, with liver extracts, as has been shown in Table IV, the larger dosages seemed to produce a proportionately smaller effect. Furthermore, when more than 1.0 ml. was injected, toxic effects were noted. These may have been due to the 0.5% phenol included in these parenteral liver extracts as a preservative.

Therefore, a series of experiments were performed to test the effect of consecutive injections on the level of metabolite excretion. Two series of experiments were run: consecutive daily injections and consecutive injections on alternate days. These results are tabulated in Table VII. Both keto acid and tyrosyl metabolite excretion are given so that comparison of these values may be made.

- 62 -

#### Table VII

## Metabolite Excretion with Consecutive Liver Extract Injections

| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   | G. pig<br>no. | Day   |        | Keto acid<br>excreted |           | Tyrosyl value<br>excreted |         |
|---|---------------|-------|--------|-----------------------|-----------|---------------------------|---------|
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               |       | mg.    | %                     | mg.       | Z                         | ml.     |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  | 26            |       |        |                       |           |                           |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               |       |        |                       |           |                           |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               |       |        |                       |           |                           | 1.01    |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               | 5     | 308    | 44.0                  | 562       | 80.3                      |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               |       |        |                       |           |                           | 1.0     |
| 9 analysis omitted, poor food consumption<br>10 288 41.2 545 77.9<br>11 217 31.0 366 52.3 1.0<br>12 268 38.3 517 73.9<br>13 288 42.4 517 76.0 1.0<br>14 302 43.2 531 75.9<br>15 384 54.9 641 91.7 1.0<br>16 348 49.8 630 90.0<br>31 1-4 187.1 19.3 221 22.5<br>5 325 34.6 411 43.8<br>6 149 15.9 185 19.7 1.0 <sup>2</sup><br>7 328 34.9 511 54.4 1.0<br>8 348 37.1 478 50.8 1.0<br>9 151 16.8 215 23.9<br>10 234 26.0 354 39.4<br>11 228 25.4 360 40.0 |               |       |        |                       | 527       | 73.2                      |         |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 8     | 285    | 40.7                  | 452       | 64.5                      | 1.0     |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 9     | analys | is omit               | ted, poor | food cons                 | umption |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 10    | 288    | 41.2                  | 545       | 77.9                      |         |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 11    | 217    | 31.0                  | 366       | 52.3                      | 1.0     |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 12    | 268    | 38.3                  | 517       | 73.9                      |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               | 13    | 288    | 42.4                  | 517       | 76.0                      | 1.0     |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$   |               | 14    | 302    | 43.2                  | 531       | 75.9                      |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               | 15    | 384    | 54.9                  | 641       | 91.7                      | 1.0     |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  |               | 16    | 348    | 49.8                  | 630       | 90.0                      |         |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$  | <b>%</b> ]    | 3 - 4 | ר מפר  | 10.8                  | 991       | 99 . F                    |         |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$  | 01            |       |        |                       |           |                           |         |
| 7       328       34.9       511       54.4       1.0         8       348       37.1       478       50.8       1.0         9       151       16.8       215       23.9         10       234       26.0       354       39.4         11       228       25.4       360       40.0   |               |       |        |                       |           |                           | 1.02    |
| 8       348       37.1       478       50.8       1.0         9       151       16.8       215       23.9         10       234       26.0       354       39.4         11       228       25.4       360       40.0   | ~.            | 7     |        |                       |           |                           |         |
| 9 151 16.8 215 23.9<br>10 234 26.0 354 39.4<br>11 228 25.4 360 40.0   | · · · · ·     |       |        |                       |           |                           |         |
| 10 234 26.0 354 39.4<br>11 228 25.4 360 40.0  |               |       |        |                       |           |                           | 1.0     |
| 11 228 25.4 360 40.0  |               |       |        |                       |           |                           |         |
|   |               |       |        |                       |           |                           |         |
| 12 222 26.4 333 39.7  |               |       |        |                       |           |                           |         |
|   |               | 12    | 222    | 26.4                  | 333       | 39.7                      |         |

(continued)

Lilly No. 377.

 $^2\mathrm{Reticulogen}$  No. 360 plus 5 mg.  $\mathrm{CoSO}_4\cdot7\mathrm{H}_2\mathrm{O}$  (Also see Table XII).

# Table VII (continued)

| G. pig    |             | Keto  | acid     | Tyrosy | l value    | In-              |  |
|-----------|-------------|-------|----------|--------|------------|------------------|--|
| no.       | Day         | excre | excreted |        | excreted   |                  |  |
|           | ب<br>۲<br>۲ | mg.   | %        | mg.    | %          | ml.              |  |
| 27        | 1           | 24.6  | 2.8      | 43.5   | 5.1        |                  |  |
| - 61      | ź           | 252   | 30.0     | 322    | 38.4       |                  |  |
| <i>A.</i> | 3           | 459   | 53.4     | 852    | 99.1       | 0.5 <sup>1</sup> |  |
| · •       | <b>4</b>    | 626   | 71.2     | 996    | 113        | 0.5              |  |
|           | 5           | 442   | 51.4     | 720    | 83.8       | 2.0              |  |
|           | 6           | 479   | 55.7     | 756    | 88.0       | 2.0              |  |
|           | 7           | 376   | 43.7     | 580    | 67.5       | 2.0              |  |
|           |             |       |          |        |            |                  |  |
| 28        | 1           | 203   | 26.1     | 295    | 37.8       |                  |  |
| 20        | 2           | 95.5  | 12.6     | 159    | 20.9       | 0.51             |  |
|           | 3           | 156   | 20.5     | 307    | 40.4       | 0.5              |  |
|           | 4           | 388   | 51.2     | 612    | 80.6       | 0.5              |  |
|           | 5           | 80.0  | 10.8     | 143    | 19.4       | 2.0              |  |
|           | 6           | 393   | 51.7     | 663    | 87.3       | 2.0              |  |
|           | 7           | 457   | 60.2     | 828    | 109        | 2.0              |  |
|           | 8           | 471   | 62.0     | 829    | 109        | 2.0              |  |
|           |             |       |          |        |            |                  |  |
| 17        | 1-5         | 23.0  | 3.0      | 66.0   | 8.5        |                  |  |
|           | 6           | 229   | 29.4     | 396    | 50.8       | 9                |  |
| 5         | 7           |       |          |        | al ate poo | rly $0.7^2$      |  |
|           | 8           | 21.6  | 2.9      | 58.9   | 7.9        |                  |  |
|           | 9           | 237   | 32.1     | 370    | 50.0       |                  |  |
|           | 10          | 306   | 41.5     | 520    | 70.4       | 1.0              |  |
|           | 11          | 324   | 43.8     | 584    | 79.0       | 1.0              |  |
|           | 12          | 248   | 33.5     | 521    | 70.5       | 1.0              |  |
|           | 13          | 226   | 30.8     | 471    | 63.7       | 1.0              |  |
|           | 14          | 186   | 24.8     | 414    | 54.5       | 1.0              |  |
|           | 15          | 274   | 36.1     | 480    | 63.2       | 1.0              |  |
|           | 16          | 282   | 36.2     | 560    | 72.0       |                  |  |
|           |             |       |          |        |            |                  |  |

<sup>1</sup>Lilly No. LS-1002-20.

<sup>2</sup>Lilly No. 377.

- 64 -

In contrast to the action of folic acid and vitamin C, it was found that the first injection produced the greatest decrease. The second injection generally had no effect, while further administration of these extracts resulted in irregular decreases, none of which were as great as the decrease in the 24-hour period after the first injection. Although no set of experiments was performed to determine the time interval required for a second injection to have as great an effect as the first, a few observations indicated that the refractory period lasted at least four or five days. In some cases, there was a slight decrease after the end of the injection series. In all cases, however, the series of injections failed to produce the steady decline in metabolite levels observed with the administration of vitamin C or folic acid over a period of days.

The problem of completely abolishing metabolite excretion with liver extracts remained unanswered. Furthermore, some new questions were raised. Was the refractory period related to the depletion of some accessory factor by the first injection? Why was there a slight decrease in metabolite levels after a series of injections was concluded? Evidently, the response of the animal to liver extract was a complex phenomenon, possible involving mobilization from body stores of unknown factors.

It became evident at this time that the response to

- 65 -

these liver extracts was quite different from the previously reported type of response to vitamin C and folic acid. It was felt that any attempt to investigate the nature of this difference was complicated by the fact that the liver extracts were complex mixtures, which differed from batch to batch and changed as they aged; and that other factors, which were present to a different extent in different animals, affected the action of a given injection.

For these reasons, two lines of investigation were initiated: the first was a study of the characteristics of the active agent in these liver preparations, and the second involved a study of factors which would enhance the action of liver extracts. An attempt to use a purified diet was part of this second study. It was hoped that the clarification of these two points would permit more control of the experimental factors and thus eliminate some of the discrepancies previously noted. The results of these experiments are given in the next three sections.

However, the main purpose of the investigation was to study the mechanism of action of the factor in these extracts, and the function of this factor in relation to the action of vitamin C and folic acid. Therefore, the work on blood, reported in the last section of the liver extract work, was initiated in conjunction with these other studies.

#### 3. Characteristics of active agent

One of the first attempts to investigate the nature of the active agent in liver extracts involved the testing of a liver dialyzate<sup>1</sup>. These preparations reactivated a dialyzed brei containing an enzyme system which oxidized tyrosine in vitro. Their vitamin C content was quite low. As the dialyzate was fractionated and the activity for the tyrosine oxidizing system in vitro concentrated, some of the more active fractions were tested for their ability to reduce the tyrosyl metabolite excretion of the vitamin C-deficient guinea pig. Some of these dialyzate injections, as shown in Table VIII, produced a considerable drop in excretory levels. Others had no effect. In many cases, however, the preparations had an irritating effect and the animal ate poorly. This might have been responsible for the decreases noted. Therefore, it was decided to await further purification of these dialyzates before additional testing was done.

At the time this work was being done in 1948, the first publications on vitamin  $B_{12}$  were appearing. Since evidence was available in this laboratory that the factor in these antipernicious anemia liver extracts responsible for their clinical action was the factor responsible for the action observed in our experiments, these publications were followed in some detail.

These dialyzates were prepared by Philip L. White.

- 67 -

# Table VIII

## Keto Acid Excretion Before and After Injection of Liver Dialyzates

| ~                |                         |     |          |      |               |                    |      |
|------------------|-------------------------|-----|----------|------|---------------|--------------------|------|
| G.<br>pig<br>no. | Keto acid<br>Wt. before |     | Keto aft |      | De-<br>crease | In-<br>jected      |      |
|                  | gm.                     | mg. | <b>%</b> | mg.  | %             | <b>%</b>           | ml.  |
| 12               | 400                     | 385 | 48.2     | 318  | 39.8          | 8.4                | 0.51 |
| 13               | 290                     | 274 | 47.3     | 214  | 36.9          | 10.4               | 1.0  |
| 14               | 370                     | 326 | 44.0     | 420  | 58.3          | +14.3 <sup>3</sup> | 0.5  |
| 15               | 400                     | 350 | 43.8     | 411  | 54.2          | +10.4              | 1.02 |
| 16               | 430                     | 310 | 36.1     | 60.0 | 7.0           | 29.1               | 1.0  |
| 18               | 410                     | 302 | 36.8     | 63.0 | 7.7           | 29.1               | 2.0  |
|                  |                         |     |          |      |               |                    |      |

<sup>1</sup>Dialyzate No. 2-205B, equivalent to 4 gm. of liver per ml.

 $^2$ Dialyzate No. 2-208B, equivalent to 5 gm. of liver per ml.

<sup>3</sup>Plus sign indicates an increased urinary excretion.

The first information on the chemical characteristics of vitamin  $B_{12}$  was reported by Smith (71). He noted that boiling this factor with 1.0 N. hydrochloric acid for one hour did not inactivate the preparation. A sample of liver extract Lilly No. 377, one of the more active extracts used in this work, was treated in this manner, neutralized and filtered. One sample so treated, equivalent to 1.0 ml. of the original extract, when injected produced a keto acid decrease from 32.2 to 14.9%; another, equivalent to 2.0 ml. of the original, produced a decrease from 46.0 to 42.5%. These results indicated that the acid treatment had not inactivated the factor to any great extent and strengthened the hypothesis that vitamin  $B_{12}$  would possess activity in reducing the tyrosine metabolite excretion of the vitamin Cdeficient guinea pig.

The direct testing of this hypothesis became possible when a vitamin  $B_{12}$  concentrate was received. This was a Merck product, called "Experimental Vitamin  $B_{12}$  Mixture, 8R3890," and containing vitamin  $B_{12}$  concentrate, charcoal and soybean flour. The concentration of the vitamin was 10.0 µg. in 2.27 gm. of the mixture. Information received later stated that this mixture was a source of the pure vitamin, uncontaminated by other liver factors.

The results of these feeding experiments with the vitamin are reported in Table IX. At the 20  $\mu$ g. level, the

- 69 -

decrease in metabolite excretion was greater than any produced with liver extract injections. Lower levels of the vitamin had less effect. One experiment in which this concentrate was fed at the 10.0  $\mu$ g. level for three successive days resulted in the same small decreases observed with liver extract after the first 24-hour period. The oral administration of a large dose of Lilly No. 377, an active liver extract when injected, is included to show the ineffectiveness of these extracts by this route. Vitamin B<sub>12</sub> has been reported to have some effect when administered orally to pernicious anemia patients (82), in contrast to the ineffectiveness of liver extracts by this route. This difference is shown in these experiments also.

The great drop in metabolite excretion at the 20 $\mu$ g. level, as compared with 1.0 ml. of the best liver extracts (recorded in Table VI), becomes more significant when the vitamin B<sub>12</sub> content of these liver extracts is examined. Elvehjem (103) has reported that 1 U. S. P. unit of Reticulogen is approximately equal to 1.0 $\mu$ g. of vitamin B<sub>12</sub> by microbiological assay. Thus 1.0 ml. of Lilly No. 377 should contain 15-20 $\mu$ g. of the vitamin, but the effect of this amount of liver extract was much smaller than the effect of that amount of the vitamin itself. The conclusion to be drawn, that vitamin B<sub>12</sub> accounted for the activity of these liver extracts in reducing metabolite excretion, must be

#### Table IX

# Keto Acid Excretion Before and After Feeding of Vitamin $B_{12}$

| G.         |     | U   | rinary (     | excretic       | n    |               | Per-<br>centage |                            |
|------------|-----|-----|--------------|----------------|------|---------------|-----------------|----------------------------|
| pig<br>no. | Wt. |     | acid<br>fore | Keto a<br>afte |      | De-<br>crease | de-<br>creasel  | Amount<br>fed <sup>2</sup> |
|            | gn. | mg. | 1/2          | mg.            | ħ    | Х             |                 | μg.                        |
| 16         | 480 | 197 | 20.5         | 345            | 35.2 | +14.7         | +71.74          | 5.0                        |
| 15         | 440 | 356 | 40.4         | 362            | 42.1 | + 1.7         | + 4.2           | 10.0                       |
| 24         | 500 | 250 | 25.0         | 209            | 21.4 | 3.6           | 14.4            | 10.2                       |
| 18         | 470 | 216 | 23.5         | 32.4           | 3.4  | 20.1          | 85.6            | 20.0                       |
| 25         | 470 | 340 | 36.2         | 378            | 40.2 | + 4.0         | +11.0           | 5.0ml <sup>3</sup>         |
|            |     |     |              |                |      |               |                 |                            |

<sup>1</sup>"Decrease" divided by "Keto acid before (%)" x 100.

 $^2$  Fed vitamin  $B_{12}$  concentrate containing 10.0 g. per 2.27 gm. plus charcoal and soybean flour.

<sup>3</sup>Liver extract Lilly No. 377.

<sup>4</sup>Plus sign indicates an increased urinary excretion.

- 71 -

qualified, since no further experiments with this concentrate were performed. The soybean flour and charcoal introduced unknown factors into the diet, and it was felt that the crystalline vitamin would soon become available. For example, it is quite possible that the protein level of the diet is important in the action of vitamin  $B_{12}$  and the soybean flour increased this considerably. Work with crystalline vitamin  $B_{12}$  was undertaken by others in this laboratory when it became available, and its activity in the guinea pig was confirmed<sup>1</sup>, but its action at the 20 µg. level was not nearly so great as that reported here. The question of whether vitamin  $B_{12}$  accounts for all of the activity of liver extract has not yet been answered.

4. Liver extract in conjunction with other factors

The two factors which had been shown to act in tyrosine metabolism, in addition to liver extracts, were folic acid and vitamin C. Small amounts of these in the natural diet used or different storage levels in the experimental animals might account for some of the variability observed in the response to liver extract. It was planned, therefore, to include these at a constant level in the diet, but in small amounts so that the animal excreted the usual high percentage of metabolites. At this point, liver extract would be

<sup>1</sup>Sealock, R. R., and Wu, M. C. Unpublished data.

- 72 -

administered. Two such experiments, in which the animal received 1.0 mg. of vitamin C daily, are reported in Table X and Figure 3. Also included in this table is an experiment in which 1.0 mg. of cobalt chloride was administered with each liver extract injection. This experiment was done after the report appeared that vitamin  $B_{12}$  was a cobalt complex (70). It was hoped that the cobalt chloride would result in an increased amount of liver extract activity.

As shown in Table X, the action of the liver extract was enhanced by the addition of 1.0 mg. of vitamin C daily. Not only were the decreases in metabolite excretion high, but there was a response to the second liver extract injection. Despite the continuation of the vitamin C, when the injections were concluded the metabolite excretion rose. Further confirmation of this action of vitamin C in enhancing the effect of liver extract is given in Figure 3. This experiment is reported in detail because of the spectacular decrease to 2.65% keto acid excretion under the influence of daily injections of Reticulogen. Finally, however, the excretion level rose despite further injections. The experiment was continued in order to observe the effect of the vitamin C alone. Sealock and Silberstein (43) have reported that 1.0 mg. of the vitamin may cause some decreases in metabolite levels. This was shown to be the case in this experiment on the 14th and 15th days (Figure 3).

- 73 -

| Ta | b | 10 | Х |
|----|---|----|---|
| 70 | U | 70 | • |

# Effect of Various Accessory Factors on Liver Extract Activity

| G. pig<br>no. | Wt. | Day |      | Keto acid<br>excretion |                  |  |
|---------------|-----|-----|------|------------------------|------------------|--|
|               | gm. |     | mg.  | ×                      | ml.              |  |
| 22            | 470 | 1-3 | 104  | 11.01                  |                  |  |
|               | 450 | 4   | 343  | 38.2                   |                  |  |
|               | 460 | 5   | 92.5 | 10.0                   | 1.02             |  |
|               | 450 | 6   | 450  | 50.0                   |                  |  |
|               | 440 | 7   | 159  | 18.1                   | 1.0              |  |
|               | 440 | 8   | 211  | 24.0                   | 1.0              |  |
|               | 440 | 9   | 142  | 16.2                   | 1.0              |  |
|               | 440 | 10  | 411  | 46.7                   |                  |  |
| 23            | 445 | 1-5 | 74.2 | 8.2                    |                  |  |
|               | 460 | 6   | 353  | 38.4                   |                  |  |
|               | 460 | 7   | 267  | 29.0                   | 1.0 <sup>3</sup> |  |
|               | 460 | 8   | 189  | 20.6                   |                  |  |
|               | 450 | 9   | 325  | 36.2                   | 1.0              |  |
|               | 440 | 10  | 331  | 37.7                   | 1.0              |  |
|               | 460 | 11  | 368  | 40.1                   |                  |  |

Animal fed 1.0 mg. vitamin C daily.

<sup>2</sup>Liver extract Lilly No. 377, 15 units per ml.

<sup>3</sup>Liver extract Lilly No. 377 plus 1 mg. CoCl<sub>2</sub>.6H<sub>2</sub>O.




FIG. 3 EXCRETION OF KETO ACID (SOLID COLUMNS) AND TYROSYL METABOLITE CALCULATED AS TYROSINE (CLEAR COLUMNS). ANIMALS FED 1.0 MG. OF ASCORDIC ACID DAILY. ARROWS SHOW LIVER EXTRACT INJECTIONS.

75

It was therefore concluded that carefully controlled experiments, using smaller amounts of vitamin C, would have to be run before any conclusions regarding a vitamin C-liver extract synergism could be made. It was decided that crystalline vitamin  $B_{12}$  ought to be used for this work in order to minimize the number of variable factors. Therefore, no further experiments with vitamin C, and none with folic acid, were run.

The results with cobalt chloride, reported in Table X, show no enhancement of liver extract action when 1.0 mg. of this compound was injected along with the liver preparation.

5. Use of purified diet

The problems involved in the use of a purified diet and the utility of this type of ration have been discussed in the Historical section. It was hoped that the exact control of vitamin and other constituents, which was possible with this diet, would permit more exact investigation of the various factors active in tyrosine metabolism. The basal diet used was a combination of those reported by Elvehjem (146) and Woolley and Sprince (144).

This was composed of 20% vitamin-free casein (Labco), 15% Cellu flour, 54.8% sucrose, 1% sucrose containing B vitamins, 4% corn oil (Mazola) fortified with fat-soluble vitamins, 5% salt mix, and 0.2% choline chloride. All but

- 76 -

one of these constituents were carefully ground together in a mortar. The corn oil was added last and incorporated by mixing in an evaporating dish, since the mortar would absorb some of the oil. After mixing, the diet was stored in the cold in a brown bottle to minimize the action of light on some of the vitamins.

The B vitamin mix was made from 17.23 gm. of sucrose, 2.00 gm. of inositol, 0.40 gm. of nicotinic acid, 0.20 gm. of <u>p</u>-aminobenzoic acid, 0.10 gm. of calcium pantothenate, 0.03 gm. of riboflavin, 0.02 gm. of pyridoxine and 0.02 gm. of thiamine. For short-time experiments it was felt that the lack of biotin would have no harmful effects. Vitamin C, folic acid and vitamin  $B_{12}$  were added to the diet only during the experimental periods as will be described. The constituents of the mix were weighed out, transferred to an evaporating dish and folded together, then ground lightly until thoroughly mixed.

The salt mixture was the one used by Elvehjem (146) and was originally prepared by Hart (160) as part of a ration for white rats. The salts used were C. P. or Reagent grade obtained from stock. To prevent caking, the highly hydrated constituents were ground in a mortar and then added to the others which had previously been ground in a ball mill.

The corn oil was made up in 400 gm. batches and each 4 gm. contained 2000 U.S.P. units of vitamin A, 100 U.S.P. units of vitamin D, 10 mg. of alpha-tocopherol and O.1 mg. of vitamin K (2-methyl-3-phytyl-1,4-naphthoquinone). This mixture was kept in the cold to prevent rancidity.

The animals on the natural stock diet were transferred to this purified diet, over a period of seven days usually, by feeding a mixture of the two diets and gradually increasing the proportion of purified diet. Vitamin C was administered orally during this period, but not during the experimental period. If this transition period was not observed, the animals showed signs of polyuria and diarrhea. Even at the conclusion of this period, however, and throughout the experiment a small amount of the stock diet (about 5% of the total diet fed) had to be placed on top of the food to induce the animals to eat. The tyrosine was incorporated with the basal diet at the 10% level, and the experimental procedure was the same as that described previously.

The main difficulty with the diet was its lack of palatability. Some animals would eat for a few days and then refuse the diet. These results were comparable to those obtained by Elvehjem (146) using a similar basal ration. The experiments reported in this section and the first two isotope experiments were successful in that the food intake was fairly consistent from day to day. This could not be predicted, however, and several experiments were started and

- 78 -

then discarded when the animals failed to eat for a day. Therefore, the remainder of the isotope experiments were run using the usual Purina chow diet.

Attempts were made to improve the palatability of the purified diet by increasing the roughage from 15 to 25%, by reducing the choline content from 0.3 to 0.1%, by decreasing the salt mixture concentration from 5.0 to 4.0%, by using an Osborne-Mendel salt mix in place of the Hart mixture, by including folic acid in the basal diet, by substituting glucose for one half of the sucrose, and by adding the ash from 30 gm. of Purina chow to 100 gm. of purified diet. This last addition had been suggested by Elvehjem (146). None of these expedients resulted in any detectable improvement in food consumption and the original diet, as outlined previously, was finally adopted.

The experiments using this purified diet were designed to examine the decreases in metabolite excretion upon administration of the three factors which had been connected with tyrosine metabolism. The results are shown in Table XI. Vitamin C and folic acid produced the expected decreases in metabolite excretion. Only keto acid figures are reported, since as usual the tyrosyl values paralleled these. However, liver extract injections failed to produce any decrease in metabolite levels. This was surprising and the only explanation advanced was that folic acid or ascorbic acid (not

- 79 -

present in this diet) might be necessary for liver extract activity. Further investigations of the action of liver extract using the purified basal diet, both with and without folic acid, are evidently necessary. These were postponed until a more satisfactory purified diet had been evolved.

The adequacy of the diet when it was consumed is shown by the small weight losses, similar to those on the Purina chow diet, observed during the experimental period. The small weight loss was noted even when the experiment lasted 15 days (Table XI, animal 41). The food intake was lower than the 20 to 30 gm. per day for a 350 gm. animal observed in experiments using the natural diet. This was probably due to the better nutritive value of the protein (casein) in the purified diet. This idea is supported by the small amount of fecal matter excreted on this diet and the lower total nitrogen content (to be reported in Section B) of the urine, indicating more efficient utilization of the ingested food.

It will be noted that the oral administration of folic acid produced a drop in metabolite excretion on the third day after administration, while the subcutaneous injection produced its effect in the next 24-hour period (Table XI, animals 49 and 53). A similar difference between these routes of administration was observed when Purina chow was used as the basal diet (to be reported in Section B).

- 80 -

## Table XI

## Keto Acid Excretion of Guinea Pigs on a Purified Diet Plus Various Supplements

| G.  |     | an an Artana<br>An Artana |   |          |       |                 | 5 T.         |
|-----|-----|---------------------------|---|----------|-------|-----------------|--------------|
| pig |     | Food                      |   | Keto     | acid  | Supple-         |              |
| no. | Wt. | intake                    | Day   | excre    | ted   | ment            | Amount       |
|     | gm. | gm.                       |   | mg.      | 70    |                 | mg.          |
| 41  | 410 | 13.4                      | 1-2   | 171      | 20.9  |                 |              |
|     | 380 | 16.6                      | 3   | 140      | 18.4  |                 |              |
|     | 380 | 12.4                      | 4   | 46.2     | 6.1   | Vita-<br>min Cl | 20.0         |
|     | 380 | 17.0                      | 5   | 29.2     | 3.9   | /               |              |
|     | 380 | 21.3                      | 6   | 254      | 33.5  |                 |              |
|     | 380 | 20.8                      | 7-9   | 175.8    | 23.1  |                 |              |
|     | 380 | 22.6                      | 10  | lost by  | error |                 |              |
|     | 370 | 22.5                      | 11  | 401      | 54.2  |                 |              |
|     | 370 | 19.8                      | 12  | 120      | 16.2  | Vita-<br>min C  | 25.0         |
|     | 370 | 24.4                      | 13  | 49.2     | 6.7   |                 |              |
|     | 370 | 21.2                      | 14-15   | 329      | 44.5  |                 |              |
|     |     |                           | a a constante da con |          |       |                 |              |
| 42  | 405 | 16.7                      | 1-4   | 120      | 15.0  |                 |              |
|     | 400 | 17.5                      | 5   | 238      | 29.8  |                 | <b>*</b> * * |
|     | 400 | 15.0                      | 6   | 128      | 16.0  | Vita-<br>min C  | 20.0         |
|     | 400 | 17.4                      | 7   | 40.0     | 5.0   |                 |              |
|     | 390 | 19.6                      | 8-9   | 41.0     | 5.3   |                 |              |
|     |     |                           | (00   | ntinued) |       |                 |              |

Administered orally as a suspension in water.

|     | G.  |     |        | 1 a.        |      |      |  |         |
|-----|-----|-----|--------|-------------|------|------|--|---------|
|     | pig |     | Food   |             | Keto | acid | Supple-                                |         |
| no. |     | Wt. | intake | Day         | excr |      |  | Amount  |
|     |     | gm. | gm.    |             | mg.  | K    |  | mg.     |
|     | 45  | 340 | 10.0   | 1-6         | 94.9 | 13.8 |  |         |
|     |     | 350 | 9.5    | 7           | 199  | 28.5 |  |         |
|     |     | 350 | 11.7   | 8           | 297  | 42.5 | Reticu-<br>logen <sup>1</sup>          | 1.0 ml. |
|     |     | 330 | 11.1   | 9           | 336  | 51.0 | Reticu-<br>logen                       | 1.0 ml. |
|     |     | 330 | 12.6   | 10          | 334  | 50.6 | Reticu-<br>logen                       | 1.0 ml. |
|     |     | 330 | 15.6   | 11-12       | 319  | 48.3 | ~~0~~                                  |         |
|     | 49  | 320 | 9.4    | r           | 149  | 23.3 |  |         |
|     | TO  | 320 | 9.7    | 2           | 236  | 36.9 |  |         |
|     |     | 320 | 6.4    | 1<br>2<br>3 | 203  | 31.7 | Folic acid <sup>2</sup><br>orally      | 15.0    |
|     |     | 320 | 8.2    | 4           | 200  | 31.3 | ······································ |         |
|     |     | 320 | 9.9    | 5           | 41.6 | 6.5  |  |         |
|     | 53  | 270 | 8.9    | 1-4         | 83.4 | 15.5 |  |         |
|     | 00  | 270 | 12.4   | 5           | 246  | 45.6 |  |         |
|     |     | 270 | 7.9    | 6           | 15.4 | 2.9  | Folic acid                             | 15.0    |
|     |     | 210 | (*7    | U U         | 10+4 | 6.3  | subcutane-                             | 70.V    |
|     |     | 270 | 10.0   | 7           | 12.3 | 2.3  | ously                                  |         |
|     |     |     |        |             |      |      |  |         |

## Table XI (continued)

Liver extract Reticulogen No. 360, injected intraperitoneally.

 $^2$  The vitamin was suspended in 0.3 ml. of H<sub>2</sub>O, then 0.4 ml. of 0.1 N. NaOH plus 0.5 ml. of phosphate buffer, pH 7.2, plus 0.4 ml. of 0.1 N. HCl were added in that order.

1

After the completion of experiments using this diet, Elvehjem (147) described a modification of the diet, which proved satisfactory. It was similar to the basal ration used in these experiments except for the addition of 2.5% potassium acetate and 0.5% magnesium oxide. A preliminary test in this laboratory<sup>1</sup>, using two animals, indicated that this diet was eaten by guinea pigs as well as the stock diet and no fluctuations in food consumption were observed.

Since administration of vitamin C and folic acid had produced considerable decreases in metabolite excretion on this diet, two isotope experiments (reported in Section B) were run. However, the variability in food consumption which made some experiments useless precluded the wide use of this purified diet. These problems may disappear with the more recently reported diet and its use, therefore, is indicated for further isotope experiments and for the study of the action of liver extract and accessory factors.

6. Effects on blood constituents

The reported excretion of tyrosine metabolites in pernicious anemia (54), coupled with the fact that antipernicious anemia liver extracts were active in decreasing tyrosine metabolite excretion in the scorbutic guinea pig (55), suggested some connection between blood formation and the

Sealock, R. R., and Wu, M. C. Unpublished data.

action of liver extract on tyrosine metabolism. The fact that liver extracts did not affect the oxidation of tyrosine <u>in vitro</u> (55) as did folic acid (121) and vitamin C (49), plus the differences between the action of these vitamins and liver extract <u>in vivo</u> reported here, further strengthened the concept of a blood formation-tyrosine relationship.

To test this hypothesis it was proposed to examine blood constituents under a series of experimental conditions which produced decreases in tyrosine metabolite excretion and see whether any correlation existed. The converse experiment, where blood constituents were varied experimentally and the effect on metabolite excretion determined, was also planned. If a relationship between blood formation and the tyrosineliver extract interaction could be demonstrated, it would be evidence that the tyrosine metabolites, which disappeared from the urine when liver extract was injected, represented the incorporation of tyrosine into some blood constituent.

The red blood cell count, hemoglobin and total nitrogen determinations were selected for study under the various experimental conditions. The problem of obtaining blood samples from the same animal several times without producing harmful effects appeared serious until it was found that the arterioles which ran along the outer edges of the animals' ears could be used. The ears were shaved, blood circulation increased by gentle rubbing and the use of xylene, and the

- 84 -

vessel nicked with a sharp razor. The first few drops were wiped away and discarded, and then three samples were drawn directly into pipettes. The procedure had to be rapid to prevent clotting.

Duplicate 0.02 ml. samples for hemoglobin determinations were drawn into diluting pipettes and then diluted to 5.02 ml. with 0.1 N. hydrochloric acid. After mixing, the samples were transferred to colorimeter tubes, which were matched so that they could be read directly in the Klett-Summerson photoelectric colorimeter, in order to avoid transfers with the small volumes available. The samples were read against distilled water as a blank, using the KS-52 filter after standing for 30 minutes. This modification of the acid hematin method (161) requires standardization of the colorimeter using blood samples whose hemoglobin content has been obtained by some independent method. This was not done, and hence colorimeter readings only were determined. These permitted comparisons to be made, however.

For determination of total nitrogen, it was convenient to pipette 4.0 ml. of the solution used for the hemoglobin determination into micro-Kjeldahl flasks. The solutions were then digested and distilled, and titrated with 0.01 N. hydrochloric acid.

The red blood cell count was determined on a third blood sample which was drawn into a Trenner pipette and diluted with Hayem's solution (162). Pipettes and the "bright-line" counting chamber used were National Bureau of Standards tested instruments. Red blood cell counts are often inaccurate when done by inexperienced personnel. Results on seven normal guinea pigs (at the start of various experiments) showed an average red blood cell count of 6.09 million per cu. mm. with a range of 5.45 to 6.93 million. One other animal had a count of 8.19 million, probably the result of some pathological condition. Wintrobe (163) has reported the red blood cell count of the guinea pig to be 5.75 million per cu. mm. with a range of 5.37 to 6.05 million. Our results were slightly high and more variable. However, it was felt that these results were good, considering the difficulties under which the blood samples were drawn. The range represents individual variation, since repeat determinations on the same animal showed much closer agreement.

The first group of experiments consisted of a study of the three blood values described above with five animals. One of these was placed on the vitamin C-deficient diet plus extra tyrosine (guinea pig no. 43), another received liver extract injections but no extra tyrosine (guinea pig no. 37), while three animals received liver extract injections in addition to the tyrosine supplement (guinea pigs nos. 29, 35, and 38). Blood analyses were made at appropriate intervals during a 20-day period in most cases. The tyrosine

- 86 -

supplement was administered in the usual manner. Each liver extract injection consisted of 1.0 ml. of Reticulogen.

Figures 4 and 5 show the fluctuations in red blood cell counts of these animals. The animal receiving tyrosine only (Figure 5) had a red blood cell count which decreased steadily. The addition of liver extract to this diet (Figure 4) seemed to result in a temporary drop in the red blood cell count, but at the end of the experiment the values were higher than at the start in all three cases. The animal receiving liver extract but no tyrosine (Figure 5) also showed an increase in the red blood cell count. If any conclusion at all can be drawn from these results, it would be that tyrosine fed to the vitamin C-deficient guinea pig decreases the red blood cell count, and the effect of liver extract would only be to remove this inhibition, since the increase with liver extract in the absence of tyrosine was comparable to the increase with liver extract when tyrosine was present. These results must be considered inconclusive in view of the variability observed.

- 87 -




FIG. 4 RED BLOOD CELL COUNT (MILLIONS PER CU. MM.) OF THREE ANIMALS RECEVING TYROSINE PLUS LIVER EXTRACT. ARROWS INDICATE SINGLE LIVER EXTRACT INJECTIONS.

88




FIG. 5 RED BLOOD CELL COUNT (MILLIONS PER CU. MM.) OF A GUINEA PIG RECEIVING TYROSINE ONLY (LEFT) AND ONE RECEIVING LIVER EXTRACT ONLY (RIGHT). ARROWS INDICATE SINGLE LIVER EXTRACT INJECTIONS.

68

The total nitrogen determinations on these five animals are shown in Figures 6 and 7. It is evident that no significant changes in the blood nitrogen occurred under these conditions. Hemoglobin values paralleled the total nitrogen values very closely and are not reported.

The metabolite excretion values of these animals were those which would be predicted under the experimental conditions. The animal which received no tyrosine (guinea pig no. 37) excreted practically no tyrosine metabolites. The animal receiving tyrosine but no liver extract (guinea pig no. 43) maintained a high level of excretion throughout the experiment (Figure 2). The changes in excretion levels of the animals on tyrosine with liver extract injection were similar to those previously reported. The data for one of these animals (guinea pig no. 38) are reported in Figure 3.

These experiments seemed to indicate that increases in red blood cells might be correlated with decreases in metabolite excretion. No clear-cut evidence was obtained, however. It was felt that one factor which may have prevented more successful experiments was the initial red blood cell count, which was normal. Any attempts to increase the red cell count would be operating in opposition to the tendency to remain at the normal level.

- 90 -




FIG. 6 TOTAL BLOOD NITROGEN (GM. PERCENT) OF THREE ANIMALS RECEIVING TYROSINE PLUS LIVER EXTRACT. ARROWS INDICATE SINGLE LIVER EXTRACT INJECTIONS.




FIG.7 TOTAL BLOOD NITROGEN (GM. PERCENT) OF A GUINEA PIG RECEIVING TYROSINE ONLY (LEFT) AND ONE RECEIVING LIVER EXTRACT ONLY (RIGHT). ARROWS INDICATE SINGLE LIVER EXTRACT INJECTIONS.

80

Therefore, it seemed advisable to study tyrosine-liver extract interaction under conditions where rapid red blood cell formation was occurring.

Cobalt polycythemia was one type of blood change which met this requirement. Orten (164) has described this condition as the result of a true stimulus to red blood cell production. Injection of 10 mg. of cobalt sulfate daily to rabbits (165) has been reported to produce an increase in red blood cells of 1.5 to 2.5 million per cu. mm. at the end of 7 days. Hemoglobin values also rose. The mechanism of this cobalt action on red blood cells has not been definitely established. Only one report on cobalt polycythemia in guinea pigs which gave the level of cobalt used was found in the literature. Sutter (166), using a total dose of 2 mg. of cobalt per 10 gm. of body weight (compound not stated), produced increases of 0.5 to 4.0 million red blood cells per cu. mm. in guinea pigs. These amounts of cobalt were close to the toxic level.

For our experiments, two animals were originally started at a level of 2.0 mg. of cobalt sulfate heptahydrate per day. When this failed to produce a definite polycythemia, three animals were started receiving 10 mg. per day for five days and then 5 mg. per day during the experimental period. Only one successful experiment was obtained, since one animal died and the other refused to to eat. Severe weight losses

- 93 -

were observed in all the experiments. The daily dose of cobalt sulfate heptahydrate was dissolved in water so that, after neutralization to pH 7.0, it was contained in a volume of 1.0 ml. Administration was subcutaneous by hypodermic or oral by pipette, as noted.

The results of the three completed experiments, recorded in Table XII, indicated that cobalt administration did change metabolite excretion. Increases in red blood cell counts took place in two of the animals, but no changes in total blood nitrogen were noted. Hemoglobin values did not change and are not reported. The levels of metabolite excretion fell prior to the injection of liver extracts and failed to reach the usual levels, even after 17 days of tyrosine feeding in the case of the animal with the greatest degree of polycythemia (guinea pig no. 31, Table XII). Decreases in metabolite excretion prior to injection are almost never observed and usually after injections cease, the metabolite excretion level rises sharply (Table VII and Figures 1, 2, and 3). The metabolite excretion pattern reported in Table XII thus differed sharply from that observed under these conditions in the absence of cobalt.

The liver extract injections produced smaller decreases than usual. Therefore, if the decrease in excretory values resulting from cobalt administration is connected with the increased blood formation observed, it would appear that the

- 94 -

#### Table XII

#### Blood and Urinary Changes of Guinea Pigs Receiving Extra Cobalt

| pig<br>no. | Day    | Total-N | R. B. C.   | Keto<br>excre | In-<br>jected |             |
|------------|--------|---------|--|---------------|---------------|-------------|
|            |        | gm. %   | millions<br>per cu. mm.                                      | mg.           | K             | <b>ml</b> . |
| 31         | 0      | 3.42    | 6.93   | en en esta    |               |             |
|            | . 7    | 3.55    | 7.15   | 200           | 18.5          |             |
|            | 8      |         | a na santa sa para ka sa | 464           | 42.9          |             |
|            | 9      |         |  | 388           | 35.9          |             |
|            | 10     | 1 × 1 × |  | 402           | 36.5          |             |
|            | 11     |         |  | 363           | 33.0          | 1.02        |
|            | 12     | 3.44    | 7.13   | 455           | 41.4          |             |
|            | 13     |         |  | 345           | 31.4          |             |
| 34         | 0      | 3.26    | 6.08   |               |               |             |
| ~          | .7     | 3.30    | 6.021  | 362           | 32.9          |             |
|            | 8      |         | 1999 1999 1999 1997 1997 1997 1997 1997                      | 625           | 59.0          |             |
|            | 8<br>9 |         |  | 530           | 50.0          |             |
|            | 10     |         |  | 450           | 41.7          |             |
|            | 11     | 3.23    | 5.76   | 363           | 33.7          | 1.0         |
|            | 12     |         | an an an an an tha an    | 376           | 35.5          |             |
|            | 13     |         |  | 367           | 34.6          |             |

Animal on vitamin C-free basal diet plus 2.0 mg. CoSO<sub>4</sub>·7H<sub>2</sub>O in O.1% glucose, orally, each day for 6 days prior to tyrosine. Cobalt continued during experimental.

<sup>2</sup>Liver extract Lilly No. 377.

## Table XII (continued)

| G.<br>pig<br>no. | Day | Total-N R. B. C.                |                         | Keto a<br>excre |      | In-<br>jected   |  |
|------------------|-----|---------------------------------|-------------------------|-----------------|------|---|--|
| n taga taga sa   |     | gm. %                           | millions<br>per cu. mm. | mg.             | %    | ml.   |  |
| 31               | 5   | 3.62                            | 7.26 <sup>1</sup>       |                 |      | n teoria de teories de la composición d<br>Composición de la composición de la comp |  |
|                  | 6   | 3.76                            | 7.82                    | 84.6            | 8.6  |   |  |
|                  | 7   |                                 |                         | 228             | 23.3 |   |  |
|                  | 8   |                                 |                         | 291             | 29.7 |   |  |
|                  | 9   | <ul> <li>Constraints</li> </ul> |                         | 145             | 15.4 |   |  |
|                  | 10  |                                 |                         | 325             | 34.6 | •   |  |
|                  | 11  |                                 |                         | 149             | 15.9 | $1.0^{2}$   |  |
|                  | 12  | 3.58                            | 9.64                    | 328             | 34.9 | 1.0   |  |
|                  | 13  |                                 |                         | 348             | 37.1 | 1.0   |  |
|                  | 14  |                                 |                         | 151             | 16.8 |   |  |
|                  | 15  |                                 |                         | 234             | 26.0 |   |  |
| ,                | 16  |                                 |                         | 228             | 25.4 |   |  |
|                  | 17  | 3.40                            | 8.27                    | 222             | 26.4 |   |  |

<sup>1</sup>Animal on stock diet plus 10 mg. CoSO<sub>4</sub>.7H<sub>2</sub>O, subcutaneously, each day for 5 days prior to tyrosine. Received one half this amount of cobalt during experimental.

<sup>2</sup>Liver extract Reticulogen No. 360.

"vitamin factors" necessary for the transformation involved are present in the animal. It would be of interest to perform this type of experiment on an animal which had been depleted of witamin  $B_{12}$ .

The results, then, of these studies on blood constituents, suggested that some relationship existed between tyrosine metabolism and red blood cell formation, and that liver extract played some part in this relationship. The evidence obtained in these few experiments, however, does not warrant any definite conclusions, but serves as a guide to further investigation.

The toxicity observed with cobalt administration suggested that some other means of inducing red blood cell formation be utilized for future work. Phenylhydrazineinduced anemia experiments were planned. It was realized that even if the results obtained were conclusive, the exact mechanism of the relationship between tyrosine and blood formation could not be obtained from these studies. However, if these studies were done with isotopically labelled tyrosine it would be possible to determine whether tyrosine was actually being incorporated into some blood constituent or whether the relationship was indirect. Since isotope studies were being initiated as a part of the comprehensive. investigation of all three factors now known to affect tyrosine metabolism, further blood studies were postponed until they could be included in the isotope program.

- 97 -

B. Experiments Using N<sup>15</sup>-L-Tyrosine

1. Methods

The general plan of these experiments involved the feeding of extra tyrosine to the vitamin C-deficient guinea pig in the usual manner. When metabolite excretion became high, vitamin supplementation was started, and under the influence of the vitamin, the tyrosine metabolites were removed from the urine. During the supplementation period, the isotopic L-tyrosine was fed. After 24 or 48 hours the animal was killed and isotope analyses made.

Supplementation with either vitamin C or folic acid removed tyrosine metabolites from the urine. By marking the tyrosine molecule, it was hoped that information would be obtained concerning the fate of the tyrosine under the influence of each vitamin, what compounds were formed from the tyrosine molecule, and whether the action of these two vitamins differed. Later, when some of the difficulties previously noted had been removed, the action of liver extracts would also be studied.

The L-tyrosine used in these experiments was marked with  $N^{15}$  in the amino group. Since evidence had appeared implicating both vitamin C and folic acid in the catabolism of tyrosine, our main interest here was to study the various urinary fractions and determine the distribution of the  $N^{15}$ 

- 98 -

in control animals, animals receiving vitamin C, and animals receiving folic acid. Feces, intestinal contents and uncaten food were also analyzed so that an accounting could be made of all of the isotopic tyrosine. Blood and carcasses were frozen and saved for future analyses.

The L-tyrosine used was synthesized<sup>1</sup> from Eastman Kodak ammonium nitrate containing 7.12 atoms % excess N<sup>15</sup>. The synthetic procedure (167) involved the Erlenmeyer azlactone synthesis, ring opening by acetone and water hydrolysis, acid hydrolysis to obtain the <u>p</u>-hydroxyphenylpyruvic acid, and catalytic hydrogenation of the carbonyl group in the presence of isotopic ammonia to obtain the DL-amino acid. The N-acetyl derivative of the racemic amino acid was resolved with D- $\propto$ phenylethylamine in order to isolate the isotopic L-tyrosine.

After feeding of the isotopic tyrosine, 24-hour urine samples were collected and the usual analyses for tyrosyl value and keto acid were run. At the conclusion of the experiment, the animal was stunned by a blow on the head, the throat was severed and blood collected in oxalate. The red cells were separated by centrifugation with the addition of 0.9% saline. Red cells and plasma, after separation, were diluted with water plus one drop of concentrated hydrochloric acid to a final volume of 50 ml. and stored in the cold.

- 99 -

<sup>&</sup>lt;sup>1</sup>Some of these experiments were performed in cooperation with Dr. Ralph K. Barclay, who synthesized and resolved the  $N^{15}$ -L-tyrosine used, and oxidized some ammonia samples to nitrogen for mass spectrometer analysis.

The intestines were removed at once and the contents washed out. The intestinal contents and uncaten food plus feces were transferred to separate 500 ml. macro-Kjeldahl flasks and digested in the usual manner. About 60 ml. of nitrogenfree, concentrated sulfuric acid was required for each flask. The digested samples were transferred to 100 ml. volumetric flasks, diluted to volume, and aliquots were distilled over in the micro-Kjeldahl still into boric acid. These were titrated and the ammonia samples then saved for isotope analysis.

The 24-hour urine samples were diluted to 100 ml. Duplicate 1 ml. aliquots were used for determination of total nitrogen by the micro-Kjeldahl method. The ammonia samples obtained were saved for isotope analysis. Duplicate 3 ml. aliquots were used for the urea analysis by a modification of the standard urease aeration method (168). The usual fivetube aeration train with the addition of a small separatory funnel in tubes 2 and 4 was used for this determination. Ten ml. of boric acid was placed in tubes 3 and 5. Tube 1 contained 6 N. sulfuric acid to remove any ammonia present in the air. The 3 ml. urine aliquots were pipetted into tubes 2 and 4. Two drops of bromthymol blue and 1 drop of phenolphthalein were added as indicators plus 2 ml. of 0.2 N. phosphate buffer, pH 6.5. The system was closed and gentle suction started. By means of the separatory funnel, one

urease tablet (Urease Dunning, 25 mg. tablet, Hynson, Westcott and Dunning, Baltimore, Md.) ground up in 5 ml. of the phosphate buffer was added to each sample. The funnels were washed down with water so that the final volume in each sample tube was approximately 20 ml. The enzyme was allowed to act for two hours at room temperature during which period the slight aeration provided stirring. The ammonia liberated by the enzyme action should turn the indicator a yellow-green color, indicating a pH of 7.0, essential for rapid urease action.

At the conclusion of the period, the solutions were made just basic to phenolphthalein with 0.1 N. sodium hydroxide added by means of the separatory funnels. Gentle suction was applied at the start and more vigorous aeration after the first hour. Capryl alcohol was added as needed. The aeration period lasted a minimum of four hours. It was found that if the aeration were too vigorous, ammonia losses occurred. When aeration was complete, the boric acid in the traps was titrated with 0.1 N. hydrochloric acid and the solutions saved for isotope analysis.

It should be noted that this procedure would carry over any ammonia originally present in the urine. However, repeated aeration tests with this size urine sample failed to show any detectable amount of ammonia as such. It is well known that the urine of herbiverous animals contains a very low percentage of ammonia. Some ammonia was recovered when 40 to 50 ml. samples of urine were made just alkaline to phenolphthalein and aerated for five hours. These results will be reported in the next section.

The residues which remained in the tubes, after the removal of the ammonia derived from urea, were made acid. They were then transferred quantitatively, in portions, to micro-Kjeldahl flasks to which one drop of nitrogen-free concentrated sulfuric acid had been added. Each portion was boiled down to a small volume over a small flame before the next was added. The usual micro-Kjeldahl digestion and distillation procedure was followed when the transfer was completed. The titrated ammonia samples were saved for isotope analysis. Blank determinations, using 3 ml. of distilled water, a urease tablet and the other constituents of the sample tubes, were run in order to determine the amount of the residual nitrogen not derived from the urine itself.

The ammonia samples from all of the determinations were made just acid to Congo red with one drop of concentrated hydrochloric acid and stored. This acidity was suitable for conversion of the ammonia samples to nitrogen gas, in which form these samples would be analyzed in the mass spectrometer. The oxidation procedure used was the method described by Rittenberg (169). The ammonium salts obtained from the Kjeldahl distillation were oxidized with alkaline hypobromite, according to the following reaction:


 $30Br^{-} + 2NH_4^{+} + 20H^{-} \longrightarrow N_2 + 5H_20 + 3Br^{-}$ 

If the solution is too acid, the following undesirable side reaction may occur:

 $Br^{-} + OBr^{-} + 2H^{+} \longrightarrow H_2O + Br_2$ 

The apparatus used for oxidizing the ammonia samples and collecting the nitrogen gas is shown in Figure 8. "A" is a 50-ml. Erlenmeyer flask with a bent neck attached and a ground-glass joint on the neck. "B" and "C" are fused together and have ground-glass fittings at each end. "B" is a 50-ml. round-bottomed flask, and "C" is a trap. "E" is a ground-glass stopcock which is interposed between the system and the mechanical and mercury diffusion pumps, which are used to evacuate the system. The right side of the apparatus is a Toeppler pump, consisting of a 250-ml. bulb, "J", with 10-mm. glass tubing fused on opposite sides. The bottom tubing extends down into "H", a 500-ml. filter flask containing 350 ml. of redistilled mercury and having a three-way stopcock, "D", fused onto the sidearm. The upper tubing from "J" leads to the three-way stopcock, "F", and a ground-glass joint into which the gas-collecting bulb, "G", fits. This collecting bulb is a 15-ml. bulb fused to a stopcock with a

- 103 -



# FIG. 8 APPARATUS FOR COLLECTION OF NITROGEN GAS.

- 104 -

ground-glass joint. This joint also fits the inlet system of the mass spectrometer. The distance from the bottom of "H" to the top of "G" is 70 cm., so that when the system is fully evacuated and then air is admitted through "D", the mercury will rise to the top of the gas bulb. A Dewar flask containing alcohol and dry ice is placed around trap "C".

The following procedure was used when operating the apparatus. The gas bulb, "G", was lubricated<sup>1</sup> and placed in position. The Kjeldahl distillate, boiled down to a volume of 3 to 4 ml., was transferred to the flask "B". This transfer need not be quantitative since it is the ratio of  $N_2^{29}$  to  $N_2^{28}$  which is being determined. The joint at "C" was greased and put in place and the alcohol-dry ice bath raised around it.

Five ml. of diluted sodium hypobromite (stock solution diluted 1:1 with water) was pipetted into flask "A" and this was then greased and placed in the downward position.

The stock solution of hypobromite was made by dissolving 200 gm. of sodium hydroxide pellets in 300 ml. of water. One half of the solution was cooled in ice and 60 ml. of bromine added over a 10-minute period, with stirring. The other one half of the alkali was then added. After two days in the cold, the sodium bromide precipitate which had formed was

<sup>1</sup>A special lubricating grease which minimized air leakage was used. This grease was Apiezon N, purchased from James G. Biddle Co., 1316 Arch St., Philadelphia, Pa. filtered off through an asbestos mat. The filtrate was stored in the cold and was stable for months. This stock solution was diluted 1:1 with water just before use.

When the procedure cited above was completed, stopcock "E" was opened and the system evacuated by means of a Cenco Hi-vac mechanical pump and a mercury diffusion pump. The mercury in "H" rises as the system evacuates. This was prevented by starting the water pump with stopcock "D" turned to position "D<sub>1</sub>". When the pressure became low, the solutions in "A" and "B" degassed and "B" froze. The vigor with which these changes occurred was controlled by opening or closing stopcock "E".

The degree of evacuation was determined by turning stopcock "F" to position "F<sub>2</sub>" and admitting air into "H" by returning the stopcock to position "D". If the system is fully evacuated, the mercury should rise to the top of the gas bulb "G". In practice, the usual vacuum attained left a small disc of air, about the size of a thumb tack, in the gas bulb. This contamination could be measured and easily corrected for in the isotope calculations.

When the system had been satisfactorily evacuated as shown by this test, the mercury was drawn back into "H" by turning its stopcock to position "D<sub>1</sub>". Stopcock "F" was left at position "F<sub>2</sub>", stopcock "E" was closed and the hypobromite solution poured into "B" by turning the flask to position "A<sub>1</sub>". The mixture in "B" was then heated gently. The reaction in "B" may be considered complete when all the ice has melted and ebullition has ceased. When the reaction was completed, the gas was introduced into "J" by turning the stopcock "F" to position " $F_1$ ". Then, by turning to position " $F_2$ " and introducing air into the system at "H" (position "D"), the nitrogen gas was moved up into the gas bulb "G" by the rising mercury. The stopcock at "G" was then closed and the stopcock at "F" opened to that position. The system was then cautiously returned to atmospheric pressure by simultaneously opening "E" and "D".

Care must be taken to admit air to all parts of the apparatus between samples to prevent a carry-over of isotope to the next sample. The various parts were then removed, rinsed with distilled water and the grease removed from the joints with carbon tetrachloride. It was not found necessary to dry the parts thoroughly between samples. The complete oxidation of a sample took about 30 minutes. The samples in the gas bulbs were analyzed in the mass spectrometer as soon as possible. Storage for more than 12 hours should be avoided.

The mass spectrometer used for these analyses was constructed here at the Institute for Atomic Research<sup>1</sup>.

<sup>&</sup>lt;sup>1</sup>The writer is indebted to Mr. Harry J. Svec of the Institute for Atomic Research, who constructed the mass spectrometer and led him through the intricacies of its operation.

It was the 60-degree, sector-type instrument with two collectors, the currents of which were balanced against each other in the usual analysis. These features produced a machine which could detect a 0.3% difference in isotope ratios. Standard samples of tank nitrogen were run before and after each series of unknown samples to check the operation of the apparatus.

Since calculation of the  $N_2^{29}:N_2^{28}$  ratio of the unknown samples involved the balancing of currents from the two collectors by means of two resistances, the relationship of these resistances to each other must be known. Direct experimental determination of this ratio, a tedious procedure, was avoided by running a standard sample of tank nitrogen and calculating the ratio of  $R_1:R_2$  by means of the equation:

(1) 
$$\frac{N_2^{29}}{N_2^{28}} = \frac{\text{Decade}}{111,111} \times \frac{R_1}{R_2}$$

The "Decade" reading was obtained experimentally and represents the adjustment of the two resistances needed to balance the currents from the two collectors. Since the  $N_2^{29}:N_2^{28}$ ratio for normal nitrogen is known, R1:R2 may be calculated by equation (1). For this instrument, the ratio of  $R_1:R_2$  was usually close to 0.99 when the nitrogen gas pressure outside the capillary leak was 5 cm. of mercury. The ratio changed

somewhat when this pressure was lower. The uncorrected  $N_2^{29}:N_2^{28}$  ratio of unknown samples was then calculated by means of formula (1) from the "Decade" reading determined experimentally for that sample, using an  $R_1:R_2$  ratio calculated as described above. The unknown and tank nitrogen samples were analyzed at the same nitrogen gas pressure outside the capillary leak.

The most widely used  $N^{15}:N^{14}$  ratio has been reported as l:265  $\pm$  8 (170). The "%  $N^{15}$ " calculated from this ratio is 0.376. This percentage has been reported as 0.38 by Nier (171). The  $N_2^{29}:N_2^{28}$  ratio for normal nitrogen of 0.00760 was then calculated from this figure. These methods of calculation have been modified slightly from those reported by Rittenberg (169). The various steps involve the conversion of an uncorrected  $N_2^{29}:N_2^{28}$  value, which has been experimentally determined on the unknown sample, to a "%  $N^{15}$ " and then to a "%  $N^{15}$  excess" over normal nitrogen. This value is then corrected for the amount of normal nitrogen.

The experimentally determined readings used for these calculations are:  $\begin{bmatrix} N_2^{29} \\ N_2^{28} \\ N_3 \end{bmatrix}_T$ ,  $(N_2^{28})_T$ ,  $(N_2^{28})_B$ , and  $(O_2^{32})_A$ ,

where T = total, B = background, and A = air. The last three values are voltage readings. The uncorrected "% N<sup>15</sup>" can then be calculated from the formula:

 $\widehat{\mathbb{O}}$ × 115 (uncorr.) = 100N where R 載 N<sup>22</sup> Ser wight €-J

8 8 8 8 8 to determine the amount of  $N_2^{30}$  present, as well as the When the N<sup>15</sup> concentration is higher than 5%, it is necessary This subtracting 0.38, the value for normal nitrogen, from the  $1.N_2^{28}$  ratio. The "% N15 (uncorr.) excess" is then obtained by formula may be used for concentrations of N15 up to 5%.

"× N15 ".

the nitrogen and correct the calculation for this, as shown below. air, as determined by the value obtained for  $(o_2^{32})_{\rm T}$ , it is must presence of normal nitrogen from air, which has contaminated pose 1ble from carbon dioxide. enriched sample. be discarded because of the presence of CO<sup>+</sup> ion derived The "% N15 (uncorr.) excess" must be corrected for the to obtain the value for the amount of contaminating Any sample containing more than 3% air If the sample contains less than 3%

(3) 
$$(N_{2}^{28})_{C} = (N_{2}^{28})_{B} + (N_{2}^{28})_{A}$$
,

For this mass spectrometer, Where  $\circ$ łł contaminating, (7) Ħ background, A DUB 11 @1**7**.

- 110 -

This value has been determined experimentally. It differs from the expected ratio of 4 because of the differences in ionization of nitrogen and oxygen in the mass spectrometer. It is then possible to calculate  $(N_2^{28})_A$  from the experimentally determined  $(0_2^{32})_A$  by means of equation (4) and thus also determine  $(N_2^{28})_C$  from equation (3). The percentage which  $(N_2^{28})_C$  is of  $(N_2^{28})_T$  determines the correction to be applied to "% N\_{(uncorr.)}^{15} excess". For example, if  $(N_2^{28})_C$  is 2% of  $(N_2^{28})_T$  then the "% N\_{(uncorr.)}^{15} excess" must be increased by 2%.

A sample calculation, representative of the values obtained, is shown below:

$$\begin{bmatrix} N_2^{29} \\ N_2^{28} \\ N_2^{28} \end{bmatrix}_{T} = 0.00830, (N_2^{28})_{T} = 9.88, (N_2^{28})_{B} = 0.068, (0_2^{32})_{T} = 0.014$$

These values are determined experimentally.

$$\% N_{(uncorr.)}^{15} = 100 \times \frac{0.00830}{2} = 0.415$$
  

$$\% N_{(uncorr.)}^{15} = 0.415 - 0.380 = 0.035$$
  

$$(N_2^{28})_A = 10.6 \times 0.014 = 0.148$$
  

$$(N_2^{28})_A = 0.068 + 0.148 = 0.216$$

$$\frac{(N_2^{28})_{C}}{(N_2^{28})_{T}} = \frac{0.216}{9.88} = 0.022$$

 $\% N_{(corr.)}^{15} = 0.035 + (0.035 \times 0.022) = 0.0358$ 

2. Results

A number of preliminary experiments designed to check the experimental procedure and examine the urinary constituents were run. In addition to the isotope comparisons, it seemed advisable to study the changes in total and urea nitrogen of the urine before and after administration of the same accessory factors which would be used when the isotopic tyrosine was fed.

The results of experiments in which the nitrogen constituents were examined before and after vitamin administration are given in Table XIII. Two of these experiments were isotope experiments. No change in total nitrogen can be seen, although considerable variability in these values is evident. The relationship of urea to total nitrogen is quite uniform, all the values falling between 73.1 and 83.7%. In all of these experiments, except the liver extract one, metabolite excretion on the pre-injection day was high, and showed the expected low value on the post-injection day reported. There was no change in metabolite excretion upon administration of

## Table XIII

# Urinary Nitrogen Constituents Before and After Vitamin Administration

| G.              | Pre-injection day |         |                          | Post-  |         |                          |                                      |
|-----------------|-------------------|---------|--------------------------|--------|---------|--------------------------|--------------------------------------|
| pig<br>no.      | Urea-N            | Total-N | <u>Urea-N</u><br>Total-N | Urea-N | Total-N | <u>Urea-N</u><br>Total-N | Supple-<br>ment                      |
|                 | mg.               | mg.     | K                        | mg.    | mg.     | K                        |                                      |
| 44 <sup>1</sup> | 296               | 361     | 82.0                     | 323    | 397     | 81.4                     | 50 mg.<br>vit. C                     |
| 47 <sup>2</sup> | 202               | 269     | 75.2                     | 185    | 232     | 79.5                     | 75 mg.<br>vit. C                     |
| 45              | 188               | 238     | 79.0                     | 185    | 250     | 74.1                     | l ml.<br>Reticu-<br>logen            |
|                 | 185               | 250     | 74.1                     | 199    | 272     | 73.1                     | l ml.<br>Reticu-<br>logen            |
| 49              | 208               | 255     | 81.7                     | 167    | 223     | 75.0                     | 15 mg. <sup>4</sup><br>folic<br>acid |
| 52 <sup>3</sup> | 285               | 354     | 80.5                     | 314    | 390     | 80.6                     | 10 mg.<br>folic<br>acid              |
|                 | 314               | 390     | 80.6                     | 326    | 390     | 83.7                     | 15 mg.<br>folic<br>acid              |

<sup>1</sup>Guinea pigs nos. 44, 45 and 49 fed on purified diet. <sup>2</sup>Animal fed on purified diet, isotope experiment. <sup>3</sup>Animal fed on Furina chow, isotope experiment.

<sup>4</sup>This dose given orally, while Guinea pig no. 52 received vitamin subcutaneously.

- 113 -

liver extract on the purified diet (Table XI). The decreases in metabolite excretion which were observed evidently cannot be correlated with changes in total or urea nitrogen under these conditions.

A total of six isotope experiments were performed. Experiments 1 and 2 utilized the purified diet, while Purina chow was used for the remainder of the experiments. Two of the animals were controls and no supplementary vitamin was given, three animals received vitamin C supplementation, and one animal received folic acid.

In all the experiments, the animals received 0.5 gm. of isotopic L-tyrosine containing 6.01% N<sup>15</sup> excess, or a total of 2.32 mg. of excess N<sup>15</sup>. Table XIV shows the type of tabulation used to convert "% N<sup>15</sup> excess" to "N<sup>15</sup> excess in mg." and "% yield" figures. Data on the absorption of the N<sup>15</sup> fed are used to illustrate these calculations. In the case of Experiments 1 through 4 the analyses represent a 24-hour period, while in Experiments 5 and 6 the animals were killed 48 hours after the isotopic tyrosine was fed. It will be noted that the absorption and excretion of the tyrosine fed was essentially complete after the first 24 hours. Furthermore, the percentage of administered tyrosine nitrogen which is absorbed is high and appears to be affected only slightly by the various vitamin supplements on both the purified and natural diets. These findings illustrate the

### Table XIV

# Isotope Absorption of Guinea Pigs Receiving N<sup>15</sup>-L-Tyrosine and Various Supplements

| Exp.<br>no. | Constit-<br>uent                       | % N <sup>15</sup><br>excess | Total-N<br>in<br>sample | N <sup>15</sup><br>excess <sup>1</sup> |                  | xcess<br>rbed | Supp <b>le-</b><br>ment |
|-------------|--|-----------------------------|-------------------------|--|------------------|---------------|-------------------------|
|             |  |                             | mg.                     | mg.                                    | mg. <sup>2</sup> | %             |                         |
|             | N <sup>15</sup> -L-<br>tyrosine<br>fed | 6.01                        | 38.7                    | 2.32                                   |                  |               |                         |
| 1           | Food-Feces<br>Int. Cont.<br>Total      | 0.100<br>0.061              | 46.8<br>204.0           | 0.0648<br>0.124<br>0.189               | 2.131            | 91.8          | vit. C                  |
| 4           | Food-Feces<br>Int. Cont.<br>Total      | 0.0977<br>0.0451            | 198.6<br>372.0          | 0.194<br>0.168<br>0.362                | 1.958            | 84.3          | vit. C                  |
| 5           | Food-Feces<br>Int. Cont.<br>Total      | 0.0388<br>0.0255            | 326.0<br>316.0          | 0.127<br>0.0806<br>0.208               | 2.112            | 91.0          | vit. C                  |
| 3           | Food-Feces<br>Int. Cont.<br>Total      | 0.140<br>0.048              | 276.0<br>348.0          | 0.386<br>0.167<br>0.553                | 1.767            | 76.2          | folic<br>acid           |
| 2           | Food-Feces<br>Int. Cont.<br>Total      | 0.193<br>0.058              | 268.0<br>163.8          | 0.518<br>0.095<br>0.613                | 1.707            | 73.7          | none                    |
| 6           | Food-Feces<br>Int. Cont.<br>Total      | 0.0402<br>0.0256            | 535.0<br>277.0          | 0.215<br>0.071<br>0.286                | 2.034            | 87.5          | none                    |
|             |  |                             |                         |  |                  |               |                         |

1% N<sup>15</sup> excess x Total-N in sample.

 $2_{\rm Difference}$  between  $N^{15}$  fed and  $N^{15}$  remaining in food and feces plus intestinal contents.

essentially physiological conditions under which these experiments were run despite the large amounts of tyrosine fed. The changes in metabolite excretion observed represent true changes in utilization of the amino acid, therefore, unless it is assumed that the amine group of tyrosine is split off prior to absorption. Further details of the experimental procedure for each experiment will be given in connection with the discussion of urinary constituents.

The poor absorption shown in Experiment 2 was due to poor food consumption, since the animal did not even eat all the supplement fed. The high "% N<sup>15</sup> excess" in the food and feces was due to uncaten tyrosine in this case.

Table XV shows the results obtained when the urinary constituents were analyzed after vitamin C supplementation. Experiment 1 utilized the purified diet and the usual low total nitrogen excretion can be seen. The animal was fed 75 mg. of vitamin C in three doses at the start and during the 24-hour period of isotope feeding. The keto acid excretion dropped from 35.4 to 10.4%. Tyrosyl values paralleled the keto acid values. In order to assure better removal of metabolites from the urine in Experiments 4 and 5, the animals received daily 25 mg. vitamin C supplements for two and three days, respectively, prior to isotope feeding. The keto acid levels before supplementation were 56.6% in Experiment 4, and 44.5% in Experiment 5. The low values which prevailed during the isotope feeding period, after supplementation, are shown in Table XV.

The amount of isotope excreted in the urine in 24 hours (Table XV) ranged from 26.7 to 39.1% in these experiments. This range resulted mainly from changes in the isotope content of the residual nitrogen, since the urea nitrogen values were almost the same in all cases, and the rise in total nitrogen values was accounted for by a similar change in the residual nitrogen. One constituent of the residual nitrogen fraction might be unchanged tyrosine. The sum of urea-plus residual-N<sup>15</sup> agreed closely with the value for total isotope nitrogen, indicating the accuracy of the fractionation procedures.

The yield figures for ammonia nitrogen do not mean much, since the long aeration period used and the small amounts of ammonia recovered make these figures unreliable. A possibility also exists that some ammonia may be lost before the urine reaches the acid in which it is collected. No ammonia could be recovered from the urine of animals fed on a purified basal diet. However, the "% N<sup>15</sup> excess" figures for ammonia are accurate since they represent a ratio. These indicate that ammonia or some compound which yields ammonia contained a high proportion of N<sup>15</sup> derived from tyrosine. In every case, the "% N<sup>15</sup> excess" for ammonia was higher than for the other fractions. Thus, despite the low "Isotope yield" shown

- 117 -

### Table XV

# Urinary Constituents of Guinea Pigs Receiving N<sup>15</sup>-L-Tyrosine and Vitamin C

| Exp.<br>no.  | Constit-<br>uent                                      | % N <sup>15</sup><br>excess          | Total-N<br>in<br>sample              | N <sup>15</sup><br>excess         | Isotope <sup>1</sup><br>yield | Keto<br>acid <sup>3</sup> |
|--------------|---|--------------------------------------|--------------------------------------|-----------------------------------|-------------------------------|---------------------------|
|              |   |                                      | mg.                                  | mg.                               | %                             | *                         |
| 1            | Total-N<br>Urea-N<br>Residual-N                       | 0.323<br>0.319<br>0.116              | 220.0<br>185.7<br>141.3 <sup>2</sup> | 0.710<br>0.590<br>0.164           | 33.3<br>27.7<br>7.7           | 10.4                      |
| 4            | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.156<br>0.169<br>0.0358<br>0.172    | 335.0<br>279.3<br>148.3<br>0.792     | 0.523<br>0.473<br>0.053<br>0.0014 | 26.7<br>24.2<br>2.7<br>0.07   | 4.63                      |
| 5<br>(Day 1) | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.171<br>0.164<br>0.111<br>0.182     | 483.0<br>332.0<br>278.7<br>4.8       | 0.825<br>0.543<br>0.310<br>0.0087 | 39.1<br>25.7<br>14.7<br>0.4   | 7.32                      |
| 5<br>(Day 2) | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.0234<br>0.0224<br>0.0133<br>0.0389 | 451.0<br>315.7<br>218.7<br>4.0       | 0.106<br>0.071<br>0.029<br>0.0016 | 5.03<br>3.37<br>1.38<br>0.08  | 5.49                      |

<sup>1</sup>Based on the N<sup>15</sup> absorbed (Table XIV).

 $2_{\rm This}$  value used in calculating N<sup>15</sup> excess. The blank value of 93.3 mg. must be subtracted to obtain the residual nitrogen of the urine only.

<sup>3</sup>Based on the amount of tyrosine fed.

in Table XV, some ammonia-yielding compound, such as glutamine, may contain significant amounts of the tyrosine nitrogen.

The nitrogen fractions collected the second day after isotope feeding (Experiment 5, Table XV) show a total of 5.03% isotope recovery. The completeness of tyrosine utilization in the first 24-hour period is again evident.

The total isotope nitrogen present in the urine of animals receiving folic acid or no supplement, as shown in Table XVI, was of the same order of magnitude as the animals receiving vitamin C. The control animals showed a urinary keto acid excretion of about 30%, while the animals receiving vitamins usually showed keto acid values of about 5%; nevertheless, the N<sup>15</sup> content of the urine was in the same range for all groups.

The animal receiving folic acid (Experiment 3) received the vitamin subcutaneously in two daily doses of 10 and 15 mg. prior to isotope feeding. The keto acid values were 30.0 and 7.26%, respectively, on these two days. This prompt response to folic acid is in contrast to the response when the vitamin was given orally. For example guines pig no. 51 received 15 mg. of folic acid orally. The keto acid value was 40.2% before supplementation for this animal, and after supplementation the daily levels were 42.0, 26.9, 5.72 and 5.50%. This delayed response to orally administered folic acid has been shown to exist on the purified basal diet also.

- 119 -

### Table XVI

# Urinary Constituents of Folic Acid-Supplemented and Control Animals Receiving N<sup>15</sup>-L-Tyrosine

| Exp.<br>no.  | Constit-<br>uent                                      | % N <sup>15</sup><br>excess          | Total-N<br>in<br>sample                     | N <sup>15</sup><br>excess          | Isotope <sup>1</sup><br>yield | Keto<br>acid <sup>2</sup> |
|--------------|---|--------------------------------------|---|------------------------------------|-------------------------------|---------------------------|
|              |   |                                      | mg.   | mg.                                | ×                             | K                         |
| 3            | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.157<br>0.143<br>0.067<br>0.137     | 390.0<br>325.7<br>155.0 <sup>3</sup><br>3.3 | 0.612<br>0.467<br>0.104<br>0.0045  | 34.7<br>26.4<br>5.9<br>0.25   | 3.47 <sup>4</sup>         |
| 2            | Total-N<br>Urea-N<br>Residual-N                       | 0.212<br>0.212<br>0.058              | 195.0<br>154.7<br>150.7                     | 0.413<br>0.328<br>0.087            | 24.2<br>19.1<br>5.1           | 33.4                      |
| 6<br>(Day 1) | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.153<br>0.158<br>0.115<br>0.152     | 498.0<br>213.3<br>355.3<br>2.8              | 0.762<br>0.337<br>0.408<br>0.0043  | 37.5<br>16.6<br>20.1<br>0.2   | 28.2                      |
| 6<br>(Day 2) | Total-N<br>Urea-N<br>Residual-N<br>NH <sub>3</sub> -N | 0.0214<br>0.0245<br>0.0220<br>0.0437 | 433.0<br>261.7<br>300.3<br>3.7              | 0.0926<br>0.064<br>0.067<br>0.0016 | 4.6<br>3.2<br>3.3<br>0.1      | 3.1                       |

<sup>1</sup>Based on amount of N<sup>15</sup> fed. <sup>2</sup>Based on amount of tyrosine fed.

 $^{3}$ This value was used in calculating N<sup>15</sup> excess. The blank value of 93.3 mg. must be subtracted to obtain the residual nitrogen of the urine only.

<sup>4</sup>Received folic acid supplement.

Of the two control experiments, Experiment 2 was run on the purified diet, the other was not. It is possible that Experiment 6 cannot be compared with the other studies, since this animal had been on the vitamin C-free basal for five days plus 13 days on the tyrosine supplement. All the other experiments lasted less than a week. Furthermore, despite the lack of supplementation, the metabolite excretion of this animal dropped rapidly during this period. The keto acid value was 48.4% prior to the two days reported in Table XVI. This drop in metabolite excretion, of unknown origin, was accompanied by a changed isotope excretion picture. The "Isotope yield" of urea was a smaller fraction of the total "Isotope yield" than that of any other animal. In fact, the residual "Isotope yield" was higher than the urea "Isotope yield", in contrast to the usual 1:5 ratio between these values. The "% N<sup>15</sup> excess" for urea, however, was quite high for this animal and the low "Isotope yield" for urea was due to a drop in the total amount of urea produced, rather than the failure of the tyrosine nitrogen only to be converted to urea.

The ammonia "% N<sup>15</sup> excess" values for the vitamin Csupplemented animals were higher than these values for the folic acid or control animals. This difference is seen more clearly when the ammonia "% N<sup>15</sup> excess" is compared to the urea "% N<sup>15</sup> excess" of the same experiment. The ratios of these values for vitamin C-supplemented, folic acidsupplemented and control animals, respectively, were 1.06, 0.96 and 0.96.

In addition to these differences in ammonia isotope concentrations, an altered distribution of the urinary nitrogenous constituents was indicated by the urea "Isotope yield" values of 16.6 and 19.1% for the control animals compared to the average urea "Isotope yield" of 26.0% for the four vitamin-supplemented animals (Tables XV and XVI). Thus, while the values for total isotopic nitrogen in the urine of all of these animals showed no significant differences, a difference in the mechanism by which the tyrosine nitrogen reaches the urine may be inferred from these changes in the distribution of the isotopic nitrogen of the various fractions when the supplementation was varied. Further control experiments and analyses of the isotope distribution in the carcasses must be made to confirm the significance of these findings.

#### IV. DISCUSSION

It has been demonstrated that antipernicious anemia liver extracts will decrease the excretion of tyrosine metabolic products by the vitamin C-deficient guinea pig receiving extra tyrosine. Injection of the best extracts resulted in a rather uniform percentage decrease in keto acid excretion of more than one half. However, injection of less active liver preparations produced a more variable response, and large doses of active preparations did not have the proportionally greater effects expected. Furthermore, one experimental extract with a high clinical activity had little action in these studies. The demonstration that vitamin  $B_{12}$ , the constituent of these extracts which is responsible for their clinical activity, was active in decreasing metabolite excretion made these results difficult to explain.

A number of similar reports have appeared in the literature concerning the action of liver extracts in growth and blood formation. Elvehjem (107) has reported that the growth increases produced by antipernicious anemia liver extracts in chicks were not proportional to their clinical activity. Vitamin  $B_{12}$  produced growth responses here also. Furthermore, certain alcohol extracts which are discarded in the preparation of these extracts were active for chick growth. Shaw

- 123 -

(112) has assayed a number of commercial liver extracts, similar to those used here, for their vitamin B12 content by microbiological assay. Preparations of different manufacturers, supposed to have the same clinical potency, varied greatly when assayed. Different batches from the same manufacturer of the same labelled potency had a vitamin  $B_{12}$ content of 0.3 to 16.0 µg. per ml. in one case, and 2.5 to 13 Mg. per ml. in another. The activity of these liver extracts was greater than would be predicted on the basis of their vitamin  $B_{1,2}$  content. This was determined by running standards of crystalline vitamin  $B_{12}$  and a solid liver preparation of known vitamin B12 content. Clinical results illustrating this same type of discrepancy have been reported by Cuthbertson and Lloyd (111), who showed that liver extracts which contained less than 10  $\mu$ g. per ml. of vitamin B<sub>12</sub> failed to produce the expected blood responses in pernicious anemia patients, while more potent extracts did. The same labelled unitage was injected in all cases.

These results plus the actual isolation of two forms of vitamin  $B_{12}$  (110) make it probable that the vitamin exists naturally as different conjugates with other unknown compounds, and also that the processing of the liver extracts results in the formation of compounds having different activities for growth of mammals, bacterial growth and blood formation.

These findings explain some of the discrepancies reported here. The ability of other vitamin factors to enhance vitamin  $B_{12}$  activity when administered along with the vitamin has also been reported and coincides with the results found using liver extract with the vitamin C-deficient guinea pig. The isolation of the various forms of the vitamin and the study of the interrelationships which exist between these forms and other factors should eventually provide a more complete explanation of the action of these liver extracts.

All the information reported concerning the function of liver extracts and vitamin  $B_{12}$  implicate them in some anabolic scheme concerned with growth or blood formation. The failure of liver extracts to produce continued abolition of metabolite excretion in our experiments, in contrast to folic acid and vitamin C, plus their lack of activity in tyrosine oxidation in vitro, indicate that a similar action may be true here. A number of studies (see Historical section) have postulated a function of vitamin  $B_{12}$  in protein utilization. Some of our experiments, where extra soybean protein was included in the diet, showed a great increase in the ability of vitamin  $B_{1,2}$  to decrease metabolite excretion. Thus it is quite possible that liver extract may act catalytically in the incorporation of tyrosine into protein or some other body constituent. The lack of sufficient amino acids or other compounds with which tyrosine can combine may then account

- 125 -

for the inability of liver extract to produce abolition of metabolite excretion for longer periods. Experiments with a purified diet, using different protein levels, should be performed to test this hypothesis. Isotope experiments similar to those already done with vitamin C and folic acid, with the tyrosine molecule marked in different positions, are also planned and would also provide information on this question by showing the location of the tyrosine molecule when liver extract was injected.

The isotope experiments reported here have been concerned with the action of vitamin C and folic acid in tyrosine metabolism, pending the establishment of experimental conditions under which greater liver extract activity can be obtained. The L-tyrosine used contained N<sup>15</sup> in the amino group.

When the isotopic tyrosine was fed to control and vitaminsupplemented animals it was found that almost all of the  $N^{15}$ was absorbed in the first 24 hours. If one considers the possibility of re-secretion into the gut, known to occur with ammonium salts, it is possible that all of the isotope eaten was absorbed during this period. Unless deamination of tyrosine in the gut is postulated, which seems improbable, these findings indicate the rapid absorption of the whole tyrosine molecule. Even the large amount of extra tyrosine consumed, therefore, is capable of being absorbed in a normal

- 126 -

manner when mixed with the food as in these experiments. The action of vitamin C and folic acid on tyrosine must be considered to be truly a metabolic relationship, since this action must occur after absorption of the molecule.

The results reported above are in conflict with those of Painter and Zilva (172). These authors fed L-tyrosine to guinea pigs and analyzed for the phenolic value of various tissues using a modified Millon's test. Their results showed a more rapid disappearance of phenolic value from the intestine in the presence of vitamin C than in its absence. It should be noted that in these experiments the tyrosine was administered in one portion by stomach tube. Poor food consumption and weight losses result from this technique. In addition, the analytical method used is positive for any phenolic molecule. In the light of the isotope findings, it is improbable that these results have physiological significance.

The analyses of urinary nitrogen constituents revealed that approximately 30% of the N<sup>15</sup> absorbed appeared in the urine in 24 hours, irrespective of the supplementary treatment. The urine of the second 24-hour period contained only 5% more of the isotope, indicating rapid utilization and elimination of the amino acid. Schoenheimer (151) fed DL-tyrosine containing N<sup>15</sup> to a rat for 10 days and found 55% of the isotope in the urine. These results show that a constant amount of the amino group of tyrosine appears in

- 127 -

the urine when the metabolite excretion is high as well as low. The action of folic acid and vitamin C on the tyrosine molecule does not involve removal of the amino group from the urine, therefore.

One hypothesis which helps to explain these results, postulates that the action of folic acid and vitamin C takes place in the liver and is concerned with tyrosine oxidation. The amino group is excreted as urea. In the absence of vitamin C, the intact tyrosine molecule is not oxidized by the liver, but is transported to the kidney where de-amination occurs and <u>p</u>-hydroxyphenylpyruvic acid appears in the urine. The amino group is also excreted, and if the enzymes of guinea pig kidney act like those of the rat, a large proportion of the amino group should appear as ammonia. Thus, in the control animals the urea N<sup>15</sup> should be lower and the ammonia N<sup>15</sup> higher than in the vitamin-supplemented animals. However, in all the animals the total N<sup>15</sup> would be the same.

Evidence for this last finding has been presented and the urea  $N^{15}$  yield for the control animals was slightly less than for the vitamin-supplemented animals, as expected. The results for the amount of ammonia  $N^{15}$  were not reliable because of the very small amount of ammonia excreted by this species, but the proportion of ammonia  $N^{15}$  was highest in the vitamin C-supplemented animals, contrary to expectations.

Further studies of the N<sup>15</sup> distribution in the carcasses

- 128 -

of these animals must be made. The isotope concentration in ornithine, citrulline and arginine, as compared to that in glutamine and asparagine, under the different experimental conditions should be particularly informative. The hypothesis mentioned above seems to fit the experimental facts on hand at present.

There are two questions about which little information exists. No data is available on the relationship of vitamin C to folic acid in this scheme. They may both act in the oxidation of tyrosine, but at different steps of the enzymatic pathway. Secondly, it is not known at what stage of the oxidation the amino group of the molecule is removed. The evidence at present (see Historical section) indicates that 2,5-dihydroxyphenylalanine is an intermediate in the oxidation of tyrosine. Therefore, de-animation is not the first oxidative step.

It should not be concluded that these hypotheses exclude other types of relationships between these vitamins and tyrosine. The anabolic functions of vitamin C and folic acid in growth and blood formation are well known. Their relationship to the action of liver extracts on tyrosine metabolism may involve an entirely different metabolic pathway than the oxidative one postulated here. This oxidative pathway is an important one, however, since the amino acid provides an energy source by this mechanism.

#### V. SUMMARY

The finding that liver extracts, used in the treatment of pernicious anemia, decreased the excretion of tyrosine metabolites by the vitamin C-deficient guinea pig has been confirmed. Suitable extracts reduced the metabolite excretion by approximately half. A vitamin  $B_{12}$ -charcoal adsorbate in a soybean flour carrier, when fed orally, had a similar action on metabolite excretion. The effect produced was approximately proportional to the amount of vitamin  $B_{12}$ administered. It has been tentatively concluded that the activity of liver extracts is due, at least in part, to their vitamin  $B_{12}$  content.

The decreases in metabolite excretion caused by liver extract were observed primarily in the 24-hour period following injections and could not be maintained by continued injections. The decreases observed were not always exactly proportional to the antipernicious anemia unitage administered. It has been concluded that other factors probably operate in conjunction with the activity of the liver extracts to produce the metabolite decreases.

The action of vitamin C or cobalt salts, in conjunction with these liver extracts, was studied. Daily administration of 1 mg. of vitamin C resulted in larger decreases in

- 130 -

metabolite excretion after liver extract injection. The cobalt salts used had no effect on the action of the liver extract. Injection of a liver dialyzate resulted in irregular decreases in metabolite excretion.

A purified diet was prepared and the action of these factors on metabolite excretion studied with this basal diet. Vitamin C and folic acid supplementation resulted in the usual cessation of metabolite excretion. In the one experiment with liver extract injections, no change in excretory values occurred.

Studies of blood constituents were made to determine whether the action of liver extracts on tyrosine metabolism was correlated with changes in red blood cell counts, total nitrogen and hemoglobin. A suggestion that decreases in metabolite excretion were correlated with increases in the number of red blood cells was noted.

Further studies of the action of vitamin C and folic acid on tyrosine metabolism were made using isotope-labelled amino acid. L-Tyrosine containing 6.01 atoms % excess N<sup>15</sup> was fed to control and vitamin-supplemented animals. It was found that 80 to 90% of the isotopic tyrosine nitrogen was absorbed from the digestive tract in the first 24 hours.

Approximately 30% of the isotopic tyrosine nitrogen absorbed by unsupplemented, vitamin C-supplemented and folic acid-supplemented animals appeared in the urine in the first 24 hours. An additional 5% was excreted in the second 24-hour period. It was concluded that the decreases in metabolite excretion produced by vitamin C and folic acid were not accompanied by changes in the amount of isotopic tyrosine nitrogen excreted.

However, the distribution of isotopic nitrogen in the urinary fractions studied differed when the supplement was varied. The nitrogen derived from the urea fraction contained more isotopic tyrosine nitrogen in the case of vitamin-supplemented animals than controls. The urine fraction which contained the greatest concentration of isotopic tyrosine nitrogen was ammonia in the case of vitamin Csupplemented animals, but this was not true for control or folic acid-supplemented animals.

#### VI. BIBLIOGRAPHY

- Bödeker, E., Das Alkapton; ein Beitrag zur Frage: welche Stoffe des Harns können aus einer alkalischen Kupferoxydlösung Kupferoxydul reduciren? Ann. 117, 98 (1861).
- 2. Wolkow, M. and Bauman, E., Über das Wesen der Alkaptonurie. Z. physiol. Chem. 15, 228 (1891).
- Falta, W. and Langstein, L., Die Entstehung von Homogentisinsäure aus Phenylalanin. Z. physiol. Chem. 37, 513 (1903).
- Neubauer, O. and Falta, W., Über das Schicksal einiger aromatischer Säuren bei der Alkaptonurie. Z. physiol. Chem. 42, 81 (1904).
- 5. Neubauer, O., Über den Abbau der Aminosäuren im gesunden und kranken Organismus. Deut. Arch. klin. Med. 95, 211 (1909).
- 6. Embden, G., Salomon, H. and Schmidt, F., Über Acetonbildung in der Leber. II. Mitteilung: Quellen des Acetons. Beitr. Chem. Physiol. Path. 8, 129 (1906).
- Blum, L., Über den Abbau aromatischer Substanzen im menschlichen Organismus. Arch. Exp. Path. Pharm. 59, 273 (1908).
- 8. Edson, N. L., Ketogenesis-Antiketogenesis. II. Ketogenesis from Amino Acids. Biochem. J. 29, 2498 (1935).
- 9. Bamberger, E., Über den Mechanismus der Umlagerung von Arylhydroxylaminen in Amidophenole. Ber. 33, 3600 (1900).
- 10. Embden, G. and Baldes, K., Über den Abbau des Phenylalanins im tierischen Organismus. Biochem. Z. 55, 301 (1913).

- 11. Moss, A. R. and Schoenheimer, R., The Conversion of Phenylalanine to Tyrosine in Normal Rats. J. Biol. Chem. 135, 415 (1940).
- 12. Dakin, H. D., Experiments Relating to the Mode of Decomposition of Tyrosine and of Related Substances in the Animal Body. J. Biol. Chem. 8, 11 (1910).
- 13. Wakeman, A. J. and Dakin, H. D., The Catabolism of Phenylalanine, Tyrosine and of Their Derivatives. J. Biol. Chem. 9, 139 (1911).
- 14. Dakin, H. D., The Chemical Nature of Alcaptonuria. J. Biol. Chem. 9, 151 (1911).
- 15. Jaffe, M., Das Auftreten von Muconsäure im Harn nach Darreichung von Benzol. Z. physicl. Chem. 62, 58 (1909).
- 16. Fromherz, K. and Hermanns, L., Über den Abbau des <u>m-Methylphenylalanins im Organismus.</u> Z. physiol. Chem. 89, 113 (1914).
- 17. Fromherz, K. and Hermanns, L., Uber den Abbau der aromatischen Aminosäuren im Tierkörper nach Versuchen am Normalen und am Alkaptonuriker. Z. physiol. Chem. 91, 194 (1914).
- Neuberger, A., Rimington, C. and Wilson, J. M., Studies on Alcaptonuria.
   Investigations on a Case of Human Alcaptonuria. Biochem. J. 41, 438 (1947).
- 19. Neuberger, A., Synthesis and Resolution of 2,5-Dihydroxyphenylalanine. Biochem. J. 43, 599 (1948).
- 20. Leaf, G. and Neuberger, A., The Preparation of Homogentisic Acid and of 2,5-Dihydroxyphenylethylamine. Biochem. J. 43, 606 (1948).
- 21. Neuberger, A., Metabolism of Proteins and Amino Acids. Ann. Rev. Biochem. 18, 260 (1949).
- 22. Arnold, R. T., Buckley, J. S., Jr. and Richter, J., The Dienone-Phenol Rearrangement. J. Am. Chem. Soc. 69, 2322 (1947).
- 23. Medes, G., A New Error of Tyrosine Metabolism: Tyrosinosis. The Intermediary Metabolism of Tyrosine and Phenylalanine. Biochem. J. 26, 917 (1932).

- 24. Gurin, S. and Delluva, A. M., The Biological Synthesis of Radio Active Adrenalin from Phenylalanine. J. Biol. Chem. 170, 545 (1947).
- 25. Raper, H. S., The Tyrosinase-Tyrosine Reaction. VI. Production from Tyrosine of 5,6-Dihydroxyindole and 5,6-Dihydroxyindole-2-Carboxylic Acid-The Precursors of Melanin. Biochem. J. 21, 89 (1927).
- 26. Mason, H. S., The Chemistry of Melanin. II. The Oxidation of Dihydroxyphenylalanine by Mammalian Dopa Oxidase. J. Biol. Chem. 168, 433 (1947).
- 27. Womack, M. and Rose, W. C., Feeding Experiments with Mixtures of Highly Purified Amino Acids. VI. The Relation of Phenylalanine and Tyrosine to Growth. J. Biol. Chem. 107, 449 (1934).
- 28. Butts, J., Dunn, M. and Hallman, L., Studies in Amino Acid Metabolism. IV. Metabolism of DL-Phenylalanine and DL-Tyrosine in the Normal Rat. J. Biol. Chem. 123, 711 (1938).
- 29. Butts, J. S., Sinnhuber, R. O. and Dunn, M. S., Effect of L-Tyrosine on Liver Glycogen of the Normal Rat. Proc. Soc. Exptl. Biol. Med. 46, 671 (1941).
- 30. Fishberg, E. H., Excretion of Benzoquinoneacetic Acid in Hypovitaminosis C. J. Biol. Chem. 172, 155 (1948).
- 31. Wallraff, E. B., Stephens, C. A., Borden, A., Holbrook, P., Hill, D., Kent, L. J. and Kemmerer, A. R., Tyrosine Excretion in Rheumatoid Arthritics and Normals. Fed. Proc. 8, 399 (1949).
- 32. Bernheim, F. and Bernheim, M., The Oxidation of Tyrosine and Phenylalanine by the Livers and Kidneys of Certain Animals. J. Biol. Chem. 107, 275 (1934).
- 33. Bernheim, F., The Oxidation of L- and DL-Tyrosine by the Livers and Kidneys of Various Animals. J. Biol. Chem. 111, 217 (1935).
- 34. Felix, K., Zorn, K. and Dirr-Kaltenbach, H., Der Abbau des Tyrosins und seiner Verwandten durch Leberund Nierenbrei. Z. physiol. Chem. 247, 141 (1937).

- 35. Felix, K. and Schaefer, H., Über das die p-Oxyphenylbrenztraubensäure abbauende Ferment. Z. physiol. Chem. 282, 142 (1947).
- 36. Felix, K. and Zorn, K., Der Abbau des Tyrosins durch Leberbrei. Z. physiol. Chem. 268, 257 (1941).
- 37. Szent-Györgyi, A., On the Mechanisms of Biological Oxidation and the Function of the Suprarenal Gland. Science 72, 125 (1930).
- 38. Morawitz, P., Pathologische Hauptpigmentierung und "Pigmentvitamine". Klin. Wschr. 13, 324 (1934).
- 39. Sealock, R. R., Ziegler, B. and Driver, R. L., The Relation of Vitamin C to the Metabolism of the Melanin Pigment Precursors, Tyrosine and Dihydroxyphenylalanine. J. Biol. Chem. 128, lxxxix (1939).
- 40. Papageorge, E. and Lewis, H. B., Comparative Studies of the Metabolism of the Amino Acids. VII. Experimental Alcaptonuria in the White Rat. J. Biol. Chem. 123, 211 (1938).
- 41. Sealock, R. R. and Silberstein, H. E., The Control of Experimental Alcaptonuria by Means of Vitamin C. Science 90, 517 (1939).
- 42. Sealock, R. R., Galdston, M. and Steele, J. M., Administration of Ascorbic Acid to an Alkaptonuric Patient. Proc. Soc. Exptl. Biol. Med. 44, 580 (1940).
- 43. Sealock, R. R. and Silberstein, H. E., The Excretion of Homogentisic Acid and Other Tyrosine Metabolites by the Vitamin C-Deficient Guinea Pig. J. Biol. Chem. 135, 251 (1940).
- 44. Sealock, R. R., Perkinson, J. D., Jr. and Basinski, D. H., Further Analysis of the Role of Ascorbic Acid in Phenylalanine and Tyrosine Metabolism. J. Biol. Chem. 140, 153 (1941).
- 45. Levine, S. Z., Marples, E. and Gordon, H. H., A Defect in the Metabolism of Aromatic Amino Acids in Premature Infants: The Role of Vitamin C. Science 90, 620 (1939).

- 46. Levine, S. Z., Marples, E. and Gordon, H. H., A Defect in the Metabolism of Tyrosine and Phenylalanine in Premature Infants. I. Identification and Assay of Intermediary Products. J. Clin. Invest. 20, 199 (1941).
- 47. Levine, S. Z., Gordon, H. H. and Marples, E., A Defect in the Metabolism of Tyrosine and Phenylalanine in Premature Infants. II. Spontaneous Occurrence and Eradication by Vitamin C. J. Clin. Invest. 20, 209 (1941).
- 48. Sealock, R. R., The Effect of Dicarboxylic Acid Administration upon the Excretion of Tyrosine Metabolites by the Guinea Pig. J. Biol. Chem. 146, 503 (1942).
- 49. Lan, T. H. and Sealock, R. R., The Metabolism in Vitro of Tyrosine by Liver and Kidney Tissues of Normal and Vitamin C-Deficient Guinea Pigs. J. Biol. Chem. 155, 483 (1944).
- 50. Sealock, R. R. and Lan, T. H., Dihydroxyphenylalanine Metabolism in the Presence of Kidney and Liver Slices of Normal and Scorbutic Guinea Pigs. J. Biol. Chem. 167, 689 (1947).
- 51. Sealock, R. R. and Goodland, R., The Oxidation of L-Tyrosine by Guinea Pig Liver Extracts. J. Biol. Chem. 178, 939 (1949).
- 52. Sealock, R. R. and Clegg, R., The Metabolism of Dihydroxyphenylalanine by Guinea Pig Kidney Extracts. J. Biol. Chem. 179, 1037 (1949).
- 53. Swendseid, M. E., Burton, I. F. and Bethell, F. H., Excretion of Keto Acids and Hydroxyphenyl Compounds in Pernicious Anemia. Proc. Soc. Exptl. Biol. Med. 52, 202 (1943).
- 54. Swendseid, M. E., Wandruff, B. and Bethell, F. H., Urinary Phenols in Pernicious Anemia. J. Lab. Clin. Med. 32, 1242 (1947).
- 55. Sealock, R. R. and Lepow, J., Antipernicious Anemia Extracts and Tyrosine Metabolism in the Scorbutic Guinea Pig. J. Biol. Chem. 174, 763 (1948).

Factor.

- 57. Jacobsen, E. and Plum, C. M., Role of Tyrosine in Pernicious Anemia. Acta Med. Scand. 120, 81 (1945). /Original not seen; abstracted in C. A. 40, 128<sup>3</sup> (1946)/.
- 58. Christensen, B. G. and Plum, C. M., The Significance of the Endocrine Glands in the Ripening of Reticulocytes. Endocrin. 41, 347 (1947).
- 59. Minot, G. R. and Strauss, M. B., Physiology of Anti-Pernicious Anemia Material. In Harris, R. S. and Thimann, K. V., Vitamins and Hormones. Vol. I, p. 269. New York, N. Y., Academic Press, Inc. (1943).
- 60. Cartwright, G. E., Huguley, C. M., Jr., Ashenbrucker, H., Fay, J. and Wintrobe, M. M., Studies on Free Erythrocyte Protoporphyrin, Plasma Iron and Plasma Copper in Normal and Anemic Subjects. Blood 3, 501 (1948).
- 61. Castle, W. B., The Etiology of Pernicious Anemia and Related Macrocytic Anemias. Harvey Lectures 30, 37 (1934-35).
- 62. Cohn, E. J., McMeekin, T. L. and Minot, G. R., The Nature of the Material Effective in Pernicious Anemia. IV. J. Biol. Chem. 84, xlix (1930).
- 63. Dakin, H. D., Ungley, C. C. and West, R., Further Observations on the Chemical Nature of a Hematopoietic Substance Occurring in Liver. J. Biol. Chem. 115, 771 (1936).
- 64. Subbarow, Y., Hastings, A. B. and Elkin, M., Chemistry of Anti-Pernicious Anemia Substances of Liver. In Harris, R. S. and Thimann, K. V., Vitamins and Hormones. Vol. III, p. 238. New York, N. Y., Academic Press, Inc. (1945).
- 65. Shorb, M. S., Unidentified Essential Growth Factors for <u>Lactobacillus lactis</u> Found in Refined Liver Extracts and in Certain Natural Materials. J. Bact. 53, 669 (1947).

J. Clin. Invest. 17, 517 (1938).

- 66. Shorb, M. S., Unidentified Growth Factors for <u>Lactobacillus lactis</u> in Refined Liver Extracts. J. Biol. Chem. 169, 455 (1947).
- 67. Rickes, E. L., Brink, N. L., Koniuszy, F. R., Wood, T. R. and Folkers, K., Crystalline Vitamin B<sub>12</sub>. Science 107, 396 (1948).
- 68. Shorb, M. S., Activity of Vitamin  $B_{12}$  for the Growth of <u>Lactobacillus</u> <u>lactis</u>. Science 107, 397 (1948).
- 69. Smith, E. L., Purification of Anti-Pernicious Anaemia Factors from Liver. Nature 161, 638 (1948).
- 70. Rickes, E. L., Brink, N. G., Koniuszy, F. R., Wood, T. R. and Folkers, K., Vitamin B<sub>12</sub>, A Cobalt Complex. Science 108, 134 (1948).
- 71. Smith, E. L., Presence of Cobalt in the Anti-Pernicious Anaemia Factor. Nature 162, 144 (1948).
- 72. Kaczka, E., Wolf, D. E. and Folkers, K., Vitamin B<sub>12</sub>.
   V. Identification of Crystalline Vitamin B J. Am. Chem. Soc. 71, 1514 (1949).
- 73. Brink, N. G., Wolf, D. E., Kaczka, E., Rickes, E. L., Koniuszy, R. R., Wood, T. R. and Folkers, K., Vitamin B<sub>12</sub>. IV. Further Characterization of Vitamin B<sub>12</sub>. J. Am. Chem. Soc. 71, 1854 (1949).
- 74. Brink, N. G. and Folkers, K., Vitamin B<sub>12</sub>. VI. 5,6-Dimethylbenzimidazole, A Degradation Product of Vitamin B<sub>12</sub>. J. Am. Chem. Soc. 71, 2951 (1949).
- 75. Smith, E. L. and Parker, L. F., Purification of Anti-Pernicious Anaemia Factor. Biochem. J. 43, Proc. viii (1948).
- 76. Ellis, B., Petrow, V. and Snook, G. F., The Isolation of the Crystalline Anti-Pernicious Anaemia Factor from Liver. J. Pharm. Pharmacol. 1, 60 (1949).
- 77. Ellis, B., Petrow, V. and Snock, G. F., The Chemistry of Anti-Pernicious Anaemia Factors. Part I. The Liberation of Phosphorus as Phosphate from Vitamin B<sub>12</sub> by Acid Hydrolysis. J. Pharm. Pharmacol. 1, 287 (1949).

- 78. West, R. and Reisner, E. H., Treatment of Pernicious Anemia with Crystalline Vitamin B<sub>12</sub>. Am. J. Med. 6, 643 (1949).
- 79. Vilter, C. F., Vilter, R. W. and Spies, T. D., The Treatment of Pernicious and Related Anemias with Synthetic Folic Acid. J. Lab. Clin. Med. 32, 262 (1947).
- 80. Heinle, R. W., Dingle, J. T. and Weisberger, A. S., Folic Acid in the Maintenance of Pernicious Anemia. J. Lab. Clin. Med. 32, 970 (1947).
- 81. Berk, L., Denny-Brown, D., Finland, M. and Castle, W. B., Effectiveness of Vitamin  $B_{12}$  in Combined System Disease. Rapid Regression of Neurologic Manifestations and Absence of Allergic Reactions in a Patient Sensitive to Injectable Liver Extracts. New Eng. J. Med. 239, 328 (1948).
- 82. Berk, L., Castle, W. B., Welch, A. D., Heinle, R. W., Anker, R. and Epstein, M., Observations on the Etiologic Relationship of Achylia Gastrica to Pernicious Anemia X. Activity of Vitamin B<sub>12</sub> as Food (Extrinsic) Factor. New Eng. J. Med. 239, 911 (1948).
- 83. Spies, T. D., Suarez, R. M., Lopez, G. G., Milanes, F., Stone, R. E., Toca, R. L., Aramburn, T. and Kartus, S., Tentative Appraisal of Vitamin B<sub>12</sub> as a Therapeutic Agent. J. Am. Med. Assoc. 139, 521 (1949).
- 84. Byerly, T. C., Titus, H. W. and Ellis, N. R., Effect of Diet on Egg Composition. II. Mortality of Embryos in Eggs from Hens on Diets Containing Protein Supplements of Different Sources. J. Nutr. 6, 225 (1933).
- 85. Rubin, M. and Bird, H. R., A Chick Growth Factor in Cow Manure. I. Its Non-Identity with Chick Growth Factors Previously Described. J. Biol. Chem. 163, 387 (1946).
- 86. Bird, H. R., Rubin, M., and Groschke, A. C., A Chick Growth Factor in Cow Manure. VII. Its Stability and Solubility. J. Biol. Chem. 174, 611 (1948).
- 87. Nichol, C. A., Robblee, A. R., Cravens, W. W. and Elvehjem, C. A., Activity of Antipernicious Anemia Preparations in Chicks. J. Biol. Chem. 170, 419 (1947).

- 88. Hill, F. W., Scott, M. L., Norris, L. C. and Heuser, G. F., Deficiency of Unidentified Vitamins in Practical Chick Rations. Poult. Sci. 23, 253 (1944).
- 89. McGinnis, J. and Carver, J. S., The Storage of an Unidentified Growth Factor or Factors in the Egg and Its Relation to Chick Growth and Mortality. Poult. Sci. 26, 457 (1947).
- 90. Rickes, E. L., Brink, N. G., Koniuszy, F. R., Wood, T. R. and Folkers, K., Comparative Data on Vitamin B<sub>12</sub> from Liver and from a New Source, <u>Streptomyces</u> griseus. Science 108, 634 (1948).
- 91. Ott, W. H., Rickes, E. L. and Wood, T. R., Activity of Crystalline Vitamin B<sub>12</sub> for Chick Growth. J. Biol. Chem. 174, 1047 (1948).
- 92. Lillie, R. J., Denton, C. A. and Bird, H. R., Relation of Vitamin B<sub>12</sub> to the Growth Factor Present in Cow Manure. J. Biol. Chem. 176, 1477 (1948).
- 93. Hartman, A. M., Dryden, L. P. and Cary, C. A., Bacterial Synthesis in the Rat of an Unidentified Growth-Promoting Factor. Fed. Proc. 8, 205 (1949).
- 94. Zucker, L. M. and Zucker, T. F., Zoopherin: A Nutritional Factor for Rats Associated with Animal Protein Sources. Arch. Biochem. 16, 115 (1948).
- 95. Emerson, G. A., Wurtz, E. and Zanetti, M. E., Vitamin B<sub>12</sub>-A Growth Factor for Young Rats. Fed. Proc. 8, 381 (1949).
- 96. Neumann, A. L., James, M. F., Krider, J. L. and Johnson, B. C., Essentiality of Vitamin B<sub>12</sub> for the Baby Pig, with Preliminary Quantitative Data. Fed. Proc. 8, 391 (1949).
- 97. Hogan, A. G. and Anderson, G. C., Vitamin B12 in Swine Nutrition. Fed. Proc. 8, 385 (1949).
- 98. Luecke, R. W., McMillen, W. N., Thorp, F., Jr. and Boniece, J. R., The Effect of Vitamin B<sub>12</sub> Concentrate on the Growth of Weanling Pigs Fed Corn-Soybean Diets. Science 110, 139 (1949).

- 99. Bosshardt, D. K., Ayres, M. M., Ydse, L. C. and Barnes, R. H., The Effect of Liver Extracts on the Utilization of Casein for Growth. J. Nutr. 32, 93 (1946).
- 100. Bosshardt, D. K., Paul, W. J., O'Doherty, K., Huff, J. W. and Barnes, R. H., Mouse Growth Assay Procedures for the "Animal Protein Factor". J. Nutr. 37, 21 (1949).
- 101. Nelson, M. M. and Evans, H. M., Lactation on Purified Diets. Arch. Biochem. 12, 229 (1947).
- 102. Emerson, G. A., Growth Promoting Activity of Vitamin B<sub>12</sub> in Rats Receiving Thyroid Substance. Proc. Soc. Exptl. Biol. Med. 70, 392 (1949).
- 103. Register, U. D., Ruegamer, W. R. and Elvehjem, C. A., An Improved Assay for a Growth Factor in Liver Extracts. J. Biol. Chem. 177, 129 (1949).
- 104. Robblee, A. R., Nichol, C. A., Cravens, W. W., Elvehjem, C. A. and Halpin, J. G., Relation Between Induced Hyperthyroidism and an Unidentified Chick Growth Factor. Proc. Soc. Exptl. Biol. Med. 67, 400 (1948).
- 105. Nichol, C. A., Dietrich, L. S., Cravens, W. W. and Elvehjem, C. A., Activity of Vitamin B<sub>12</sub> in the Growth of Chicks. Proc. Soc. Exptl. Biol. Med. 70, 40 (1949).
- 106. Bosshardt, D. K., Huff, J. W., Paul, W. J. and Barnes, R. H., Animal Protein Factor and Growth of Mice Fed Diets Containing Succinylsulfathiazole. Fed. Proc. 8, 378 (1949).
- 107. Nichol, C. A., Robblee, A. R., Cravens, W. W. and Elvehjem, C. A. The Growth Response of Chicks to Antipernicious Anemia Preparations. J. Biol. Chem. 177, 631 (1949).
- 108. Stokstad, E. L., Jukes, T. H., Pierce, J., Page, A. C., Jr. and Franklin, A. L., The Multiple Nature of the Animal Protein Factor. J. Biol. Chem. 180, 647 (1949).

- 109. Cunha, T. J., Hopper, H. H., Burnside, J. E., Pearson, A. M., Glasscock, R. S. and Shealy, A. L., Effect of Vitamin B<sub>12</sub> and APF Supplement on Methionine Needs of the Pig. Arch. Biochem. 23, 510 (1949).
- 110. Pierce, J. V., Page, A. C., Jr., Stokstad, E. L. and Jukes, T. H., Crystallization of Vitamin B<sub>12b</sub>. J. Am. Chem. Soc. 71, 2952 (1949).
- 111. Cuthbertson, W. and Lloyd, J., The Vitamin  $B_{12}$  Concentration in Liver Extracts and a Note on the Relationship Between Clinical Response and  $B_{12}$ Dosage. J. Pharm. Pharmacol. 1, 705 (1949).
- 112. Shaw, G. E., The Growth Activity for <u>Lactobacillus</u> <u>lactis</u> Dorner of Commercial Liver Extracts. J. Pharm. Pharmacol. 1, 701 (1949).
- 113. Shive, W., Ravel, J. M. and Eakin, R. E., An Interrelationship of Thymidine and Vitamin B<sub>12</sub>. J. Am. Chem. Soc. 70, 2614 (1948).
- 114. Shive, W., Ravel, J. M. and Harding, W. M., An Interrelationship of Purines and Vitamin B<sub>12</sub>. J. Biol. Chem. 176, 991 (1948).
- 115. Wright, L. D., Skeggs, H. R. and Huff, J. W., The Ability of Thymidine to Replace Vitamin B<sub>12</sub> as a Growth Factor for Certain Lactobacilli. J. Biol. Chem. 175, 475 (1948).
- 116. Schaeffer, A. E., Salmon, W. D. and Strength, D. R., Relation of Vitamin B<sub>12</sub> to Choline Requirement of the Rat and Chick. Fed. Proc. 8, 395 (1949).
- 117. Gillis, M. B. and Norris, L. C., Effect of the Animal Protein Factor on the Requirement for Methylating Compounds. J. Biol. Chem. 179, 487 (1949).
- 118. Hartman, A. M., Dryden, L. P. and Cary, C. A., A Role of Vitamin B<sub>12</sub> in the Normal Mammal. Arch. Biochem. 23, 165 (1949).
- 119. Jukes, T. H. and Stokstad, E. L., Pteroylglutamic Acid and Related Compounds. Physicl. Revs. 28, 51 (1948).

- 120. Rodney, G., Swendseid, M. and Swanson, A., Tyrosine Oxidation by Livers from Rats with a Sulfasuxidineinduced Pteroylglutamic Acid Deficiency. J. Biol. Chem. 168, 395 (1947).
- 121. Rodney, G., Swendseid, M. E. and Swanson, A. L., The Role of Pteroylglutamic Acid in Tyrosine Oxidation by Rat Liver Tissue. J. Biol. Chem. 179, 19 (1949).
- 122. Woodruff, C. W. and Darby, W. J., An in Vivo Effect of Pteroylglutamic Acid upon Tyrosine Metabolism in the Scorbutic Guinea Pig. J. Biol. Chem. 172, 851 (1948).
- 123. Woodruff, C. W., Cherrington, M. E., Stockell, A. K. and Darby, W. J., The Effect of Pteroylglutamic Acid and Related Compounds upon Tyrosine Metabolism in the Scorbutic Guinea Pig. J. Biol. Chem. 178, 861 (1949).
- 124. Papell, J., The Effect of Liver Extract Administration on Tyrosine Metabolism. Unpublished M. S. Thesis. Ames, Iowa, Iowa State College Library (1947).
- 125. Govan, C. D., Jr. and Gordon, H. H., The Effect of Pteroylglutamic Acid on the Aromatic Amino Acid Metabolism of Premature Infants. Science 109, 332 (1949).
- 126. Cartwright, G. E. and Wintrobe, M. M., Experimental Production of a Nutritional Macrocytic Anemia in Swine. Fed. Proc. 8, 351 (1949).
- 127. Bethell, F. H., Meyers, M. C. and Neligh, R. B., Vitamin B<sub>12</sub> in Pernicious Anemia and Puerperal Macrocytic Anemia. J. Lab. Clin. Med. 33, 1477 (1948).
- 128. Bennett, M. A., Some Observations on the Role of Folic Acid in Utilization of Homocystine by the Rat. Science 110, 589 (1949).
- 129. Ruegamer, W. R., Brickson, W. L., Torbet, N. J. and Elvehjem, C. A., Response of Dogs to Liver Extracts Containing the Pernicious Anemia Factor. J. Nutr. 36, 425 (1948).

- 130. Nichol, C. A., Harper, A. E., Dietrich, L. S. and Elvehjem, C. A., Effect of Folic Acid, Liver Extract and Vitamin B<sub>12</sub> on Hemoglobin Regeneration in Chicks. Fed. Proc. 8, 233 (1949).
- 131. Williams, J. N., Jr., Nichol, C. A. and Elvehjem, C. A., Relation of Dietary Folic Acid and Vitamin  $B_{12}$  to Enzyme Activity in the Chick. J. Biol. Chem. 180, 689 (1949).
- 132. Dinning, J. S., Keith, C. K., Totter, J. R. and Day, P. L., Effects of Pteroylglutamic Acid, Injectable Liver Extract and Ascorbic Acid on Dietary Glycine Toxicity. Fed. Proc. 8, 381 (1949).
- 133. Johnson, B. C. and Dana, A. S., Ascorbic Acid Therapy of Pteroylglutamic Acid-Deficient Rats. Science 108, 210 (1948).
- 134. Lepp, A., Moore, P. R., Elvehjem, C. A. and Hart, E. B., Effect of Vitamin C on Hemoglobin Production in Chicks. Poult. Sci. 26, 594 (1947).
- 135. Abbott, L., Jr., and Salmon, C., Jr., Experimental Alkaptonuria in the White Rat on High Tyrosine Diets. J. Biol. Chem. 150, 339 (1943).
- 136. Lanyar, F., Über experimentelle Alkaptonurie bei der weissen Ratte. Z. physiol. Chem. 278, 155 (1943).
- 137. Lanyar, F., Über experimentelle Alkaptonurie bei der weissen Maus. Z. physiol. Chem. 275, 225 (1942).
- 138. Glynn, L. E., Himsworth, H. P. and Neuberger, A., Pathological States Due to Deficiency of the Sulphur-Containing Amino Acids. Brit. J. Exptl. Path. 26, 326 (1945).
- 139. Neuberger, A. and Webster, T. A., Studies on Alcaptonuria. 3. Experimental Alcaptonuria in Rats. Biochem. J. 41, 449 (1947).
- 140. Martin, G. J. and Hueper, W. C., Biochemical Lesions Produced by Diets High in Tyrosine. Arch. Biochem. 1, 435 (1943).
- 141. Martin, G. J., Toxicity of Tyrosine in Normal and Vitamin-Deficient Animals. J. Am. Pharm. Assoc. 36, 187 (1947).

- 143. Woolley, D. W. and Sprince, H., Identification of Folic Acid as One of the Unknown Dietary Essentials for Guinea Pigs. J. Biol. Chem. 153, 687 (1944).
- 144. Woolley, D. W. and Sprince, H., The Nature of Some New Dietary Factors Required by Guinea Pigs. J. Biol. Chem. 157, 447 (1945).
- 145. Kuiken, K. A., McCoy, R. H., Schultze, M. O. and King, C. G., Simplified Diets for the Guinea Pig. J. Nutr. 27, 385 (1944).
- 146. Booth, A. N., Elvehjem, C. A. and Hart, E. B., The Importance of Bulk in the Nutrition of the Guinea Pig. J. Nutr. 37, 263 (1949).
- 147. Roine, P., Booth, A. N., Elvehjem, C. A. and Hart, E. B., Importance of Potassium and Magnesium in Nutrition of the Guinea Pig. Proc. Soc. Exptl. Biol. Med. 71, 90 (1949).
- 148. Schoenheimer, R. and Rittenberg, D., Studies in Protein Metabolism. I. General Considerations in the Application of Isotopes to the Study of Protein Metabolism. The Normal Abundance of Nitrogen Isotopes in Amino Acids. J. Biol. Chem. 127, 285 (1939).
- 149. Rittenberg, D., Keston, A. S., Rosebury, F. and Schoenheimer, R., Studies in Protein Metabolism. II. The Determination of Nitrogen Isotopes in Organic Compounds. J. Biol. Chem. 127, 291 (1939).
- 150. Schoenheimer, R. and Ratner, S., Studies in Protein Metabolism. III. Synthesis of Amino Acids Containing Isotopic Nitrogen. J. Biol. Chem. 127, 301 (1939).
- 151. Schoenheimer, R., Ratner, S. and Rittenberg, D., Studies in Protein Metabolism. VII. The Metabolism of Tyrosine. J. Biol. Chem. 127, 333 (1939).

- 152. Winnick, T., Friedberg, F. and Greenberg, D. M., Studies in Protein Metabolism with Compounds Labeled with Radioactive Carbon. I. Metabolism of DL-Tyrosine in the Normal and Tumor-Bearing Rat. J. Biol. Chem. 173, 189 (1948).
- 153. Reid, J. C. and Jones, H. B., Radioactivity Distribution in the Tissues of Mice Bearing Melanosarcoma after Administration of DL-Tyrosine Labeled with Radioactive Carbon. J. Biol. Chem. 174, 427 (1948).
- 154. Weinhouse, S. and Millington, R. H., Ketone Body Formation from Tyrosine. J. Biol. Chem. 175, 995 (1948).
- 155. Schepartz, B. and Gurin, S., Intermediary Metabolism of Phenylalanine Labeled with C<sup>14</sup>. Fed. Proc. 8, 248 (1949).
- 156. Schepartz, B. and Gurin, S., The Intermediary Metabolism of Phenylalanine Labeled with Radioactive Carbon. J. Biol. Chem. 180, 663 (1949).
- 157. Lerner, A. B., On the Metabolism of Phenylalanine and Tyrosine. J. Biol. Chem. 181, 281 (1949).
- 158. Penrose, L. and Quastel, J. H., Metabolic Studies in Phenylketonuria. Biochem. J. 31, 266 (1937).
- 159. Folin, O. and Ciocalteu, V., On Tyrosine and Tryptophane Determinations in Proteins. J. Biol. Chem. 73, 627 (1927).
- 160. Phillips, P. H. and Hart, E. B., The Effect of Organic Dietary Constituents upon Chronic Fluorine Toxicosis in the Rat. J. Biol. Chem. 109, 657 (1935).
- 161. Hawk, P. B., Oser, B. L. and Summerson, W. H., Practical Physiological Chemistry. 12th ed., p. 559. Philadelphia, Penn., The Blakiston Co. (1947).
- 162. Wintrobe, M. M., Clinical Hematology. 2nd ed., p. 248. Philadelphia, Penn., Lea and Febiger (1949).
- 163. Wintrobe, M. M., Variations in the Size and Hemoglobin Content of Erythrocytes in the Blood of Various Vertebrates. Folia Hemat. 51, 32 (1933).

- 164. Orten, J. M. and Bucciero, M. C., The Effect of Cysteine, Histidine and Methionine on the Production of Polycythemia by Cobalt. J. Biol. Chem. 176, 961 (1948).
- 165. Barron, A. G., Polycythemia (caused) by Cobalt. The Action of Ascorbic Acid. Bol. soc. quím., Perú 11, 137 (1945). /Original not seen; abstracted in C. A. 40, 54789 (1946)/.
- 166. Sutter, J., Cobalt et Hyperglobulie. Compt. rend. soc. biol. 116, 994 (1934).
- 167. Barclay, R. K., Oxidation of L-Tyrosine by Liver Tissue. Unpublished Ph. D. Thesis. Ames, Iowa, Iowa State College Library (1949).
- 168. Hawk, P. B., Oser, B. L. and Summerson, W. H., Practical Physiological Chemistry. 12th ed., p. 823. Philadelphia., Penn., The Blakiston Co. (1947).
- 169. Rittenberg, D., The Preparation of Gas Samples for Mass-Spectrographic Isotope Analysis. In Wilson, D. W., Preparation and Measurement of Isotopic Tracers. p. 31. Ann Arbor, Mich., J. Edwards (1946).
- 170. Wahl, M. H., Huffman, J. F. and Hipple, J. A., Jr., An Attempted Concentration of the Heavy Nitrogen Isotope. J. Chem. Physics 3, 434 (1935).
- 171. Nier, A. O., The Mass Spectrometer and Its Application to Isotope Abundance Measurements in Tracer Isotope Experiments. In Wilson, D. W., Preparation and Measurement of Isotopic Tracers. p. 11. Ann Arbor, Mich., J. Edwards (1946).
- 172. Painter, H. A. and Zilva, S. S., The Influence of Bactericidal Agents and of the Absence of L-Ascorbic Acid on the Accumulation of Hydroxyphenyl Compounds in the Large Intestine of Guinea Pigs after the Consumption of High Doses of L-Tyrosine. Biochem. J. 43, 398 (1948).